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Chapter 1. General Introduction 
1.1 Inflammation 
 
The body’s adaptive and immediate response to tissue and cell damage by pathogens, harmful stimuli, 
or physical injuries is called inflammation. It is a beneficial immune response to fight foreign matter from 
tissue injury and initiate the healing of tissue structure and function. Inflammation is classified into two 
categories: (1) acute and (2) chronic ones.
[1]
 Acute inflammation is a body’s short-term responses that result 
mostly in healing and repairing damaged tissues and cells. Chronic inflammation, on the other hand, is a 
prolonged inflammatory response that can cause damage to the tissues. The prolonged and persistent 
inflammation is uncontrolled and it is associated with many chronic human diseases such as cancer, multiple 
sclerosis, arthritis, and allergy. An uncontrolled inflammatory response can be harmful to the host either in 
an acute setting, such as during an infection, or in a chronic context, such as arthritis.
[2]
   
Inflammation includes a series of complex reactions that involves cytokines, enzymes, growth factors, 
and nitric oxide (NO) produced by macrophage cells. The onset of infections and inflammation will lead to 
an increased level of enzymes and signal proteins in the affected area. This biological response, triggered and 
promoted by cytokines, is a protective mechanism where the injurious stimuli, pathogens, irritants, and 
infections will be removed via phagocytosis to protect the cells or tissues and initiate the healing process.
[3]
 
During inflammation, cell signaling proteins known as cytokines play an important role by controlling the 
host’s responses to infections and injuries as inflammatory or anti-inflammatory reactions. Some cytokines 
promote or make infections and diseases to escalate and are referred as pro-inflammatory cytokines. Other 
cytokines control and reduce the level of inflammation and promote healing processes, and are known as 
anti-inflammatory cytokines.
[4]
  
The presence of foreign matters such as chemicals and pathogens at the cell surface will be detected by 
cell receptors and trigger the activation of nuclear factor kappa B (NF-κB). The interactions of the receptors 
results in transmitting signals to nucleus where the activation of a selective set of genes takes place through 
transcriptional and posttranscriptional mechanisms. For example, the activated NF-κB will be detached from 
the inhibitory protein kappa B (IκB) and released into the cell nucleus and binds onto the deoxyribonucleic 
acid (DNA). The attachment of NF-κB to the DNA will induce enzymes such as cyclooxygenase 2 (COX-2) 
and inducible nitric oxide synthase (iNOS) to synthesize prostaglandin, thromboxane and nitric oxide, 
respectively as an inflammatory response.
[5]
 During the onset of inflammatory responses, cells also release 
pro-inflammatory cytokines to help the process which sometimes results in chronic condition causing cell 
death and tissue damages. To control this condition, the immune system will try to balance the inflammation 
process by releasing anti-inflammatory cytokines that regulate and lower inflammation level where the 
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infections are cured and cells are repaired (Figure 1). After the onset of inflammation, whether it is chronic 
or acute, cytokines play an important role. For example, interleukin 1 (IL-1) and tumor necrosis factor α 
(TNF- ) are pro-inflammatory cytokines. They produce fever, inflammation, tissue destruction, and 
sometimes resulting in shock and death. On the other hand, IL-4, IL-10, and IL-13 are potent 
anti-inflammatory cytokines. Anti-inflammatory cytokines have the ability to suppress and inhibit the 
synthesis of pro-inflammatory cytokines resulting in tissue recovery and healing.
[4]
  
 
 
Figure 1. Diagram showing inflammatory and anti-inflammatory process 
 
Over the years, many researches have been conducted to better understand and treat diseases associated 
with inflammation. Though inflammation is very critical for survival, over production of inflammatory 
cytokines and mediators can cause infection and diseases. Many of the anti-inflammatory drugs inhibit the 
synthesis of inflammatory mediators such as eicosanoids. Eicosanoids are signaling molecules that play a 
vital role in an inflammatory response, which are produced as a result of oxidation of arachidonic, 
eicosapentanoic, and dihomo-gamma-linolenic acids (fatty acids containing 20 carbons). The phospholipase 
A2 (PLA2) catalyzes the conversion of glycerophospholipids from the cell membrane to arachidonic acid, 
and their inhibition could potentially block the synthesis of all eicosanoids.
[6]
 It is very important to identify 
anti-inflammatory agents that could selectively inhibit the activation and synthesis of enzymes and signaling 
molecules that promote inflammation.   
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1.2 Anti-inflammatory Agents 
 
Anti-inflammatory agents are drugs that stop or reduce the level of inflammation and promote healing and 
tissue recovery process. The anti-inflammatory drugs work by suppressing the enzymes that produce 
cytokines that promote inflammation and tissue damage. Ibuprofen (isobutylphenylpropanoic acid) and 
aspirin (Figure 2) are two of the well-known non-steroidal anti-inflammatory drugs. Ibuprofen and aspirin 
alleviates inflammation by inhibiting cyclooxygenases 2 (COX-2) from synthesizing prostaglandins and 
thromboxanes that promotes inflammation.  
 
 
 
Figure 2. Two of the common anti-inflammatory drugs 
 
There are many anti-inflammatory and analgesic drugs available that are marketed: 1) steroidal, 2) 
non-steroidal (NSAIDs), and 3) opioids (Figure 3). These anti-inflammatory and analgesic drugs are very 
selective on the type of inflammatory mediators they work against. Steroidal anti-inflammatory drugs such as 
corticosteroids inhibit phospholipase A2 activity by preventing the release of arachnoid acid (AA) while the 
NSAIDs such as indomethacin and aspirin inhibits cyclooxygenase 2 (COX-2) and the synthesis of 
prostaglandins.
[6]
 The use of opioids like morphine and codeine, unlike steroidal and NSAIDs, act directly on 
the receptors located on the neuronal cell membranes by inhibiting the release of neurotransmitters. 
Unfortunately, opioids are problematic as a result of their adverse properties that include addiction, tolerance, 
and depression of breathing, nausea and chronic constipation.
[7]
 Likewise, the use of steroidal 
anti-inflammatory drugs has led to the development of tolerance, physical, and mental dependency on these 
drugs.
[8]
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Figure 3. Representative anti-inflammatory and analgesic drugs 
 
Many scientific studies, current and ongoing, have been conducted using lipopolysaccharide 
(LPS)-stimulated macrophage bioassays to investigate the anti-inflammatory activities of natural products. 
Bacterial LPS is a well-known stimulus that induces the release of inflammatory mediators such as nitric 
oxide (NO), TNF-α, and induce the up-regulation of pro-inflammatory cytokines.[9] However, the over 
production and the prolonged presence of excess NO in the cells and tissues will result in the reaction of NO 
with superoxide radicals to form harmful peroxynitrites. Many chronic human diseases like asthma, 
rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, and Alzheimer’s disease and various 
human cancers have been linked to chronic inflammation.
[10]
 Over the years many novel natural products 
with diverse and promising bioactivities have been isolated from both marine and terrestrial organisms. 
Amongst them are number of chemical entities with potent anti-inflammatory and anti-oxidant properies. 
Some notable ones that have recently been isolated include polyphenols and flavonoids,
[11]
 terpenoids,
[12]
 
steroids,
[13]
 and cyclic peptides.
[14]
 These chemical compounds inhibit enzymes from producing cytokines 
that promotes inflammation and cause tissue and cell damage.  
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Figure 4. Natural product anti-inflammatory agents 
 
Many natural products with anti-inflammatory activities have been isolated and successfully synthesized. 
Cyclomarin A was isolated from a culture of Streptomyces (Figure 4). It showed cytotoxicity towards cancer 
cells but its anti-inflammatory properties were also significant.
[14c]
 Solomonamide A, a polyketide, with a 
unique chemical structure was isolated from the marine sponge Theonella swinhoei. It showed significant 
reduction of inflammation in the carrageenan-induced paw edema model in rats at 100 μg/kg.[15] These two 
compounds showed promising results as potential non-steroidal anti-inflammatory drugs.  
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1.3 Aim of the study 
 
Inflammation affects every aspects of human health. As such, it is very important to identify new 
anti-inflammatory agents that are non-steroidal or non-opioid with minimum side effects to meet the growing 
need for proper and effective anti-inflammatory drug. Therefore, in this study lipopolysacaride 
(LPS)-stimulated murine RAW264.7 macrophage cells will be used in a bioassay-guided isolation of 
anti-inflammatory agents from marine sponge Stylissa massa.  
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Chapter 2. Isolation and Structure Elucidation of Bioactive Natural 
Products from the Marine Sponge Stylissa massa 
2.1 Introduction 
 
Marine environment is an excellent source from which many biologically active compounds with 
interesting chemical architecture have been isolated. Interestingly, this environment has not been fully 
studied. There has been an increased interest by researchers to investigate the marine environment with the 
aim of identifying new bioactive compounds. Marine sponges are of the organisms that have been 
extensively studied, and from them many new bioactive compounds have been obtained. Marine sponges are 
widespread across the ocean and recently, a number of peptides with unique chemical structures and 
biological activities have been isolated from marine sponges.
[1]
 Several classes of biologically active 
compounds have been isolated from them including cyclic peptides. The number of bioactive compounds 
isolated from marine sponges has been rapidly increasing. Apart from other bioactive metabolites, only a 
considerable number of amino acids 
[2]
 and peptides 
[1a, 3]
 have been discovered from marine organisms. 
Several species of marine sponge have continued to receive the attention of researchers as sources of new 
compounds.
[1b, 1c]
 Haliclamide 
[4]
 and calyxamide B 
[5]
  (cytotoxic against carcinoma and P388 murine 
leukemia cell, respectively) are some of the bioactive natural products that have been isolated from marine 
sponges (Figure 5).   
 
 
 
Figure 5. Bioactive natural products isolated from marine sponges 
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Cyclic peptides, unlike their linear counterparts, are very stable and resistant to enzymatic digestion and 
can remain in the human digestive system without losing their bioactivity. The cyclic nature of the peptides 
provides stability and a wide spectrum of bioactivities and may guide the development of more effective and 
stable drugs.
[6]
 However, the downside of the cyclic peptides as drugs is that they cannot be taken orally 
because of their impermeability across the cell membranes. Therefore, they are used mostly used as 
injections.  
Several cyclic peptides have been isolated from marine sponges including Axinella,
[1b, 8]
 Stylotella,
[9]
 
Phakellia,
[10]
 Hymeniacidon,
[7, 11]
 and Stylissa 
[12]
 species. Amongst the cyclic peptides that have been 
isolated, several cyclic peptide which are rich in proline residues such as stylissamide X 
[5]
 and hymenamide 
A 
[7]
 were isolated from marine sponge Stylissa sp. and Haliclona sp., respectively (Figure 6).   
  
 
 
Figure 6. Cyclic peptides isolated from marine sponges 
Many biologically active peptides contain proline or polyproline residues, such as shown in Figure 6, 
and play important roles in many biological processes such as cell motility, signal transduction, transcription, 
and immune responses.
[13]
 Peptides modulate the immune system and increase the activity level in the case of 
infection or diseases, and are also predominantly active against bacteria.
[14]
 Some proline-rich peptides 
induce the immune system to produce white blood cells and allow immune cells and antibodies to enter the 
tissue to counteract against infections and diseases. This process is very important in inflammatory responses. 
The conformational structures of proline motifs in a peptide chain appear to imply important structural and 
biological function.
[15]
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2.2 Extraction and Isolation 
2.2.1 Extraction of Crude Material 
 
In a continuous study on bioactive compounds from marine organisms and in an effort to isolate new 
bioactive molecules, an orange marine sponge Stylissa massa was collected from Loloata island, Papua New 
Guinea, in 2010. The crude material was first extracted with 80% aq. MeOH (Scheme 1). The methanolic 
extract was concentrated and partitioned with water and ethyl acetate (EtOAc). The EtOAc layer was 
concentrated and partitioned with 90% aq. MeOH and n-hexane. The 90% aq. MeOH layer was further 
partitioned with 60% aq. MeOH and dichloromethane (CH2Cl2) to obtain MeOH and CH2Cl2 layers. These 
two layers were active in bioassay by inhibiting NO production in lipopolysaccharide (LPS)-stimulated 
murine RAW264.7 macrophage cells.  
 
 
 
Scheme 1. Extraction of crude material 
Inhibition of NO production in LPS-stimulated 
RAW264.7 cells at 100 μg/mL 
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2.2.2 Separation of the Dichloromethane Layer 
 
Guided by the NO bioassay, the CH2Cl2 layer was further separated into seven fractions by silica gel open 
column chromatography (Scheme 2). The screening of the fractions in NO bioassay indicated that the two 
fractions, fr. 2-1 and fr. 2-3, were bioactive by inhibiting NO production in LPS-stimulated murine 
RAW264.7 macrophage cells. Further separation of fr. 2-1, once by Yamazen automated silica gel medium 
pressure liquid chromatography (MPLC) followed by RP-HPLC [Develosil ODS-HG-5 ɸ 20 × 250 mm], 
resulted in the isolation of compound A.  
 
 
 
Scheme 2. Isolation of compound A 
 
Inhibition of NO production in LPS-stimulated 
RAW264.7 cells at 100 μg/mL 
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On the other hand, fr. 2-3 was further separated into seven fractions with silica gel open chromatography 
(Scheme 3). The fr. 2-3-1, was further separated with reverse-phase high pressure liquid chromatography 
(RP-HPLC, Develosil ODS-HG-5 ɸ 20 × 250 mm) in 75% MeOH to afford bioactive fractions, fr. 2-3-1-1 
(compound B, 5.0 mg), fr. 2-3-1-4 (compound C, 3.6 mg), and fr. 2-3-1-7 (12.0 mg). The fr. 2-3-1-7 was 
active but not pure as indicated by several spots on a HPTLC. It was subjected again to RP-HPLC [Develosil 
ODS-HG-5 ɸ 20 × 250 mm] and separated with 85% methanol to obtain fr. 2-3-1-7-2 (compound D, 3.0 
mg).   
 
 
 
Scheme 3. Isolation of compounds B, C, and D 
 
 
Inhibition of NO production in LPS-stimul 
RAW264.7 cells at 100 μg/mL 
 
Inhibit f O production in LPS-stimulated 
RA  cel s at 10  μg/mL 
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2.3 Biological Evaluation of Compounds Isolated from the Marine Sponge 
Stylissa massa 
 
The NO inhibitory activity of the four compounds isolated from the marine sponge Stylissa massa was 
analyzed and compared against a known non-steroidal anti-inflammatory drug indomethacin (Table 1). 
Compound D showed potent activity by inhibiting the production of NO in LPS-stimulated murine 
RAW264.7 macrophage cells (EC50 = 87 μM) with indication of slight cytotoxicity (IC50 =110 μM) at 100 
μg/mL. Compound C showed weak inhibition of NO production (164 μM) without affecting the cell viability. 
The compounds A and B showed very weak inhibition of NO production (250 and 280 μM, respectively). 
 
Table 1. Biological evaluation of the natural products isolated from the marine sponge Stylissa massa 
 
Compound NO inhibition 
 EC50, μM 
Cell viability  
IC50, μM 
Selectivity index 
 IC50/EC50 
Indomethacin 140 280 2.0 
A 250 >350 >1.4 
B 280
*
 >200 >0.7 
C 164 >200 >1.2 
D 87 110 1.3 
*value obtained by extrapolation 
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2.4 Structure Elucidation of the Natural Products Isolated from the Marine 
Sponge Stylissa massa  
2.4.1 Structure Elucidation of Compound A 
 
Compound A was obtained as an off white amorphous solid. The molecular ion in the low resolution 
positive EI/MS spectrum was observed at m/z 283 [M]
+
 with an isotopic pattern (281, 283, and 285) with a 
ratio of 1:2:1 that indicated the presence of two bromine (Br) atoms (Figure 7). The odd mass m/z 283 
indicated the presence of an odd number of nitrogen atom. Based on the analysis high resolution GC-EI-MS 
data (m/z 282.94), the molecular formula was established as C6H5Br2NO2 with a calculated mass of m/z 
282.8667 for 
79
Br and 
81
Br requiring four degrees of unsaturation. 
 
 
 
Figure 7. HR-EI-MS spectrum of compound A 
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Figure 8. 
1
H
 
NMR spectrum of compound A (400 MHz, CD3OD) 
 
 
 
Figure 9. 
13
C NMR spectrum of compound A (100 MHz, CD3OD) 
 
The 
1
H NMR spectrum (Figure 8) showed two singlet proton signals, a methoxy proton resonating at 3.73 
ppm and an aromatic proton at 6.81 ppm. The peaks were all singlet which indicated that there was no 
coupling between the protons. The 
1
H NMR in CDCl3 revealed proton signals at 3.87, 6.88, and 9.09 ppm. 
The proton signal at 9.09 ppm was not previously observed in CD3OD, which indicted the presence of a 
17 
 
proton attached to a heteroatom (NH or OH). The 
13
C NMR spectrum (Figure 9) reveals the presence of a 
methoxy carbon resonating at 52.1 ppm, aromatic carbons at 100.4, 108.4, 118.6, 125.3 ppm, and a carbonyl 
carbon resonating at 161.5 ppm. The integration of proton signals showed three methoxy protons and an 
aromatic proton. Based on the analysis of heteronuclear single quantum coherence (HSQC) spectrum, the 
carbon signal resonating at 52.1 ppm was directly connected to the methoxy proton while the carbon atom 
resonating at 118.6 ppm was directly connected to the aromatic proton. The proton and carbon signals at 1.8 
ppm and 24 ppm were considered as impurities because there was no correlation between the other proton 
and carbons in the 2D NMR analysis.   
The heteronuclear multiple bond correlation (HMBC) correlation between the methoxy proton (3.73 ppm) 
and the carbonyl carbon (161.0 ppm) was observed. Similarly, a correlation was observed between the single 
aromatic proton (6.81 ppm) and the two aromatic carbons (108.4 and 125.3 ppm) (Figure 10). Based on the 
1D and 2D NMR data and degree of unsaturation, the two partial structures and the remaining atoms CBr2 
were connected. Although there are still several possible structures, the whole structure was elucidated 
considering occurrence in nature (Figure 11). 
 
 
 
Figure 10. HMBC correlation and partial structures 
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Figure 11. HMBC correlations and the established structure of compound A 
 
The chemical structure and the molecular formula of compound A were identical to a known compound. 
Therefore, the 
1
H and 
13
C NMR in CDCl3 was compared with the data of the authentic sample (Table 2). The 
comparison of the NMR data showed minor differences in the proton (△H –0.06 - –0.12 ppm) and carbon        
(△C –0.1 - –1.3 ppm) signals.  Based on this analysis, compound A was identified as a known compound 
4,5-dibromomopyrrole-2-carboxylic acid methyl ester (Figure 12). It was previously isolated from a Turkish 
and a Maltese marine sponge Agelas oroides,
[16]
 and also from a Sri Lankan marine sponge Lissodendotyx 
sp.
[17]
  
 
Table 2. Comparison of 
1
H and 
13
C NMR data of compound A and a known compound  
 
Compounds 
1
H NMR (CDCl3) 
13
C NMR (CDCl3) 
Compound A δH 6.81 (1H, s), 3.72 (3H, s) δC 52.1, 100.4, 108.4, 118.6, 125.3, 161.5 
Known compound  δH 6.87 (1H, s), 3.84 (3H, s) δC 53.2, 101.7, 108.3, 119.1, 125.0, 161.3 
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Figure 12. 4,5-dibromopyrole-2-carboxylic acid methyl ester 
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2.4.2 Structure Elucidation of Compound B 
 
Compound B was obtained as an off-white solid. The MALDI-TOF MS showed a pseudomolecular ion 
peak at m/z 753.418 [M+H]
+
. The molecular formula was determined as C38H56N8O8 by high resolution 
ESI/MS (HR-ESI-MS) which was supported by 
1
H and 
13
C NMR spectra. The infrared (IR) spectroscopy 
absorptions at 3326, 3319, 1653, 1223, and 777 cm
-1
 suggested the presence of and amino and amide 
carbonyl groups.  
The 
1
H NMR spectrum (Figure 13) showed the presence of aliphatic, aromatic and alpha proton signals. 
Similarly, the 
13
C NMR showed aliphatic, aromatic, heteroatom-connected carbons and eight carbonyl 
carbon signals (Figure 10). The detailed 2D NMR analysis revealed the presence of seven amino acid 
residues: 3 valines (Val), a pair of prolines (Pro), a single phenylalanine (Phe) and an asparagine (Asn). The 
six doublet methyl groups corresponded to the three Vals and the aromatic protons corresponded to Phe 
residues. From the eight carbonyl carbons (Figure 14), seven corresponded to the seven amino acid residues 
while the remaining carbonyl carbon at 173 ppm was assigned to the amide in Asn moiety. The seven 
carbonyl carbons could not be assigned to their respective amino acids due to the excessive overlapping 
signals (171.56-174.54 ppm) as a result of duplicate amino acid residues.  
From the data base search, compound B was found as a cyclic peptide, the molecular formula and 
constituent amino acids of which corresponded to those of a known compound, axinastatin 1,
[18]
 a cyclic 
heptapeptide that was isolated from a marine sponge. The amino acids and the number of residues also 
corresponded exactly to the known compound (Figure 15).   
 
 
Figure 13. 
1
H NMR spectrum of compound B (600 MHz, CD3OD)  
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Figure 14. 
13
C NMR spectrum of compound B (150 MHz, CD3OD) 
 
 
 
 
 
Figure 15. Axinastatin 1 
 
 
 
 
 
22 
 
 
 
Figure 16. MALDI-TOF MS/MS spectrum of compound B 
 
To establish the planar structure and amino acid connectivity of compound B, MS/MS analysis was 
performed (Figure 16). From the MS/MS analysis three major fragmentation pathways were identified which 
confirmed the amino acid connectivity in compound B. The first fragmentation pathway started with the 
opening of the macro cycle at the Val
7
 amide bond and loss of carbonyl (28) gave 725 and loss of 69 
(corresponds to loss of Pro
6
) left 656 (Val
5
-Val
4
-Phe
3
-Pro
2
-Asn
1
-Val
7
), and loss Val
5
 left 557 
(Val
4
-Phe
3
-Pro
2
-Asn
1
-Val
7
), loss of another Val
4
 left 458 (Phe
3
-Pro
2
-Asn
1
-Val
7
), and the loss of Phe
3
 leaves 
310 (Pro
2
-Asn
1
-Val
7
). The second fragmentation sequence began with the ring opening at amide bond of Pro
2
 
and loss of carbonyl (28) left 725 and loss of 86 left 639 (which corresponds to a loss of Asn
1
) 
(Val
7
-Pro
6
-Val
5
-Val
4
-Phe
3
-Pro
2
), loss of Val
7
 left 540 (Pro
6
-Val
5
-Val
4
-Phe
3
-Pro
2
), loss of Pro
6
 leaves 443 
(Val
5
-Val
4
-Phe
3
-Pro
2
), loss of Val
5
 left 344 (Val
4
-Phe
3
-Pro
2
), and the loss of another Va
l4
 left 244 (Phe
3
-Pro
2
). 
The third pathway began with the protonation of Pro
6
 and the subsequent loss of Val
5
 left 654 
(Val-Phe-Pro-Asn-Val-Pro), loss of another Val
4
 left 555 (Phe-Pro-Asn-Val-Pro), loss of Phe
3
 left 408 
(Pro-Asn-Val-Pro), loss of Pro
2
 left 311 (Asn-Val-Pro), and finally the loss of Asn
1
 left 196 (Val-Pro). The 
three partial sequences (Pro
6
-Val
5
-Val
4
-Phe
3
, Asn
1
-Val
7
-Pro
6
-Val
5
-Val
4
 and Val
5
-Val
4
-Phe
3
-Pro
2
-Asn
1
) 
(Figure 17) were identified which covers the whole structure of compound B (Figure 15). From these 
sequences the cyclic structure was deduced as cyclo[Asn
1
-Pro
2
-Phe
3
-Val
4
-Val
5
-Pro
6
-Val
7
].    
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Figure 17. Peptide sequence of compound B determination by MS/MS analysis 
24 
 
 
 
Figure 18. 
1
H NMR spectra of compound B (600 MHz, CDCl3) 
 
 
Table 3. Comparison of the 
1
H and 
13
C NMR spectra of authentic axinastatin 1 and compound B 
 
Amino 
 
Axinastatin 1 (CDCl3) Compound B (CDCl3) 
Acids Atom 
13
C 
1
H (mult, J (Hz), integrtn) 
13
C 
1
H (mult, J (Hz), integrtn) 
Phe CO 172.4  *172.4  
 α 55.6 4.68 (dt, 4.8, 10.8, 1H) 55.6 4.81 (dddd, 4.9, 9.7, 11.2, 1H) 
 β 37.6 2.94 (1H) 37.9 2.96 (dd, 1.9, 13.6, 1H) 
   3.20 (1H)  3.22 (dd, 5.2, 14.8, 1H) 
 1 137.6  137.7  
 2/6 128.9 7.15, 2H 128.4 7. 22 (d, 7.5, 2H) 
 3/5 126.5 7.23, 2H 128.5 7.28 (dd, 1.0, 7.3, 2H ) 
 
4 126.5 7.17 126.7 7.22 (t, 3.7, 1H) 
 
NH  7.74  7.55 (d, 9.6, 1H) 
Pro
1
 CO 170.7  *170.4  
25 
 
 
α 63.3 4.06 (dd, 9.7, 7.6) 63.7 4.11 (dd,7.4, 10.1, 1H) 
 
β 29.5 1.34 29.7 1.38 (m, 1H) 
  2.23  2.32 (m, 1H) 
 γ 25.8 1.80 25.9 1.74 (m, 1H) 
   1.92  1.99 (m, 1H) 
 δ 48.0 3.46 48.2 3.53 (m, 1H) 
   3.57 (t, 8.3)  3.63 (t, 8.0, 1H) 
Asn CO 169.3  *169.2  
 α 50.3 4.57 (q, 4.2) 50.4 4.66 (q, 4.9, 1H ) 
 β 35.8 2.95 36.4 2.98 (dd, 9.8, 11.5, 1H ) 
   3.23  3.28 (dd, 4.9, 14.2, 1H) 
 CO 172.8  *172.7  
 NH2  5.52  5.46 (d, 2.0,1H) 
   7.69  6.39 (s, 1H) 
 NH  8.06 (d, 4.9 )  8.04 (d, 5.2, 1H) 
Val
1
 CO 172.2  *171.3  
 α 62.2 4.02 (t, 8.2) 62.3 4.09 (t, 7.7, 1H) 
 β 29.5 2.35 29.6 2.40 (td, 6.8, 13.7, 1H) 
 δ 18.7 1.01, 3H 18.9 1.00 (d, 1.2, 3H) 
  19.9 1.05, 3H 20.1 1.083 (d, 2.5, 3H) 
 NH  8.25 (d, 7.9)  8.26 (d, 8.0, 1H) 
Pro
2
 CO 171.4  *172.1  
 α 61.2 4.53 (d, 7.0) 61.4 4.57 (d, 7.4, 1H) 
 β 31.1 1.88 31.4 1.93 (m, 1H) 
   2.55  2.61 (dd, 6.2, 11.9, 1H) 
 γ 21.7 1.67 22.0 1.85 (m, 1H) 
   1.92  1.99 (m, 1H) 
 δ 46.0 3.46 46.2 3.51 (m, 1H) 
   3.69  3.75 (m, 1H) 
Val
2
 CO 171.4  *171.7  
 α 58.6 4.13 (dd, 7.14, 4.1) 58.6 4.18 (dd, 4.2, 7.3, 1H) 
 β 30.0 1.96 30.3 1.99 (m, 1H) 
 γ 18.9 1.02, 3H 19.0 1.077 (d, 4.6, 3H) 
  19.2 0.93, 3H 19.5 0.996 (d, 5.3, 3H) 
 NH  7.44  7.33 (d, 9.1,1H ) 
Val
3
 CO 171.4  *171.3  
 α 57.3 4.23 (t, 9.5) 57.5 4.24 (t, 9.5, 1H) 
26 
 
 β 29.2 2.02 29.2 2.03 (m, 1H) 
 γ 18.5 0.94, 3H 18.6 1.065 (d, 6.7, 3H) 
  19.5 0.92, 3H 20.0 0.986 (d, 6.3, 3H) 
 NH  7.44  6.75(d, 4.0, 1H) 
Note: * 7 carbonyl carbons (170-173 ppm) could not be assigned to their respective amino acid residue due to overlapping carbon 
signals. 
 
The 
1
H and 
13
C spectral data of compound B in CDCl3 was fully characterized and compared with the 
literature spectral data of an authentic sample (Table 3). The differences of proton chemical shifts were 
observed but were negligible. On the other hand the carbon chemical shits were almost identical. The 
negligible differences in the chemical shifts would have occurred due to the differences in NMR conditions 
such as temperature and concentration of the samples used in the NMR measurements, which are often 
reported to cause difference in proton NMR data for peptides. Based on this analysis including mass, 
molecular formula, and the peptide sequence it was identified as a known cyclic peptide axinastatin 1. 
Axinastatin 1 was reported to show cytostatic activity towards P338 lymphocytic leukemia cell growth.
[19]
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2.4.3 Structure Elucidation of Compound C 
 
Compound C was obtained as a colorless oil. The ESI/MS showed a pseudomolecular ion peak at m/z 
938.65 [M+H]
+
. The molecular formula was established as C50H67N9O9 by high resolution ESI/MS analysis. 
The IR spectroscopy absorptions at 3405, 3026, 1652, and 760 cm
-1
 suggested the presence of amino, 
hydroxyl, and amide carbonyl groups.  
 
 
 
Figure 19. 
1
H NMR spectrum of compound C (600 MHz, CD3OD) 
 
The 
1
H NMR spectrum (Figures 19) showed the chemicals shifts revealing the presence of aromatic, alpha, and 
aliphatic protons. Similarly, the carbon chemical shifts indicated the presence of aromatic, alpha, aliphatic, and 
carbonyl carbons. The 
1
H and 
13
C NMR, HSQC, and COSY spectra were used to assign all of the protons and 
carbons to their respective amino acid residues. The presence of eight carbonyl carbons and alpha protons 
confirms the presence of eight amino acid residues. The detailed partial structure analysis revealed eight amino 
acid residues: three prolines (Pro), and one each of leucine (Leu), threonine (Thr), tryptophan (Trp), valine (Val), 
and phenylalanine (Phe).  
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Figure 20. 
13
C NMR spectrum of compound C (150 MHz, CD3OD) 
 
The connectivity of each amino acid residue could not be determined by HMBC spectrum alone because 
the chemical shifts of eight carbonyl carbons were overlapping (171.31-173.96 ppm). In order to identify the 
amino acid connectivity and the sequence the MALDI-TOF MS/MS analysis was utilized as with compound 
B (Figure 21).  
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Figure 21. MALDI-TOF MS/MS spectrum of compound C 
 
Three major fragmentation pathways were identified which confirms the amino acid connectivity and 
sequence in compound C. The first fragmentation pathway started with the opening of the macro cycle at the 
Pro
3
 amide bond and the subsequent loss of Val
2
 left m/z 839 (Thr
1
-Leu
8
-Pro
7
-Phe
6
-Pro
5
-Trp
4
), loss of 
Thr
1
-Leu
8
 leaves m/z 625 (Pro
7
-Phe
6
-Pro
5
-Trp
4
-Pro
3
), the loss of Pro
7
 left m/z 528 (Phe
6
-Pro
5
-Trp
4
-Pro
3
), the 
loss of Phe
6
 left m/z 382 (Pro
5
-Trp
4
-Pro
3
). The second fragmentation pathway started with a ring opening at 
Pro
5
, which after a loss of carbonyl (-28) left m/z 910 and the loss of a dipeptide Trp
4
-Pro
3
 left m/z 627 
(Val
2
-Thr
1
-Leu
8
-Pro
7
-Phe
6
-Pro
5
), and the loss of Val
2
 left m/z 528 (Thr
1
-Leu
8
-Pro
7
-Phe
6
-Pro
5
). The third 
pathway showed ring opening at the amine bond of Val
2
 and the loss of Val
2
 from the N-terminus left m/z 
839 (Pro
3
-Trp
4
-Pro
5
-Phe
6
-Pro
7
-Leu
8
-Thr
1
), and the loss of Pro
3
-Trp
4
 left m/z 556 (Pro
5
-Phe
6
-Pro
7
-Leu
8
-Thr
1
) 
followed by the loss of Pro
5
-Phe
6
 left m/z 312 (Pro
7
-Leu
8
-Thr
1
).  
From the fragmentation patterns three partial peptide sequences were identified that covered the whole 
structure of compound C: Val
2
-(Thr
1
-Leu
8
)-Pro
7
-Phe
6
, (Trp
4
-Pro
3
)-Val
2
, and Val
2
-Pro
3
-Trp
4
-Pro
5
-Phe
6
 
(Figure 23). By connecting these partial sequences the planar structure was elucidated as a 
cyclo[Pro-Trp-Pro-Phe-Pro-Leu-Thr-Val]. The structure of compound C corresponded to a known 
compound axinellin C (Figure 23).
[20]
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Figure 22. Peptide sequence determination by MS/MS analysis 
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Figure 23. Axinellin C 
 
Table 4. Comparison of the 
1
H and 
13
C NMR spectra of axinellin C and compound C 
 
 Amino   Axinellin C (CD3OD) Compound C (CD3OD) 
Acid Atom 
13
C 
1
H (mult, J (Hz), integrtn) 
13
C 
1
H (mult, J (Hz), integrtn) 
Thr
1
 α 58.1 4.97 (1H, dd, 3.2, 8.4 Hz) 58.46 5.01 (d, 3.7 Hz, 1H) 
  β 68.4 4.31 (1H, m) 69 4.35 (m, 1H) 
  γCH3 19.4 1.19 (3H, d, 6.4 Hz) 19.8 1.23 (d,6.4 Hz, 3H) 
  CO 171 
 
*171.3 
 
   NH   7.72 (d, 6.8 Hz, 1H) ** 
 
Val
2
 α 58.2 4.46 (1H, d, 8.8 Hz) 58.48 4.70 (d, 11.1 Hz, 1H) 
  β 29.7 2.33 (m, 1H) 30.1 2.35 (m, 1H) 
  γ1CH3 20.3 0.93 (3H, d, 6.8 Hz) 21.2 0.99 (d, 6.4 Hz, 3H) 
  γ2CH3 18.7 0.84 (3H, d, 8.0 Hz) 19.1 0.94 (d, 6.7 Hz, 3H) 
  CO 171.4 
 
*171.9 
 
   NH   7.74 (d, 7.9 Hz, 1H) ** 
 
Pro
3
 α 62.3 4.14 (1H, dd, 7.6 Hz) 62.7 4.17 (t, 8.5 Hz, 1H ) 
  β 30.7 2.24 (1H, m) 31.1 2.29 (m, 1H) 
      1.81 (1H, m) 
 
1.84 (m, 1H) 
  γ 25.8 2.07 (1H, m) 26.1 2.07 (m, 1H) 
      1.90 (1H, m) 
 
1.90 (m, 1H) 
  δ 49.2 3.95 (1H, m) 49.65 3.72 (dd, 6.8, 10.9 Hz, 1H) 
32 
 
      3.68 (1H, m) 
 
3.66 (m, 1H) 
  CO 172.4 
 
*172.7 
 
Trp
4
 α 56.8 4.34 (1H, m) 57.2 4.39 (dd, 2.2, 7.9 Hz, 1H ) 
  β 25.8 3.55 (1H, m) 26.2 3.61 (dd, 6.5, 12.7 Hz, 1H ) 
      3.39 (1H, m) 
 
3.44 (dd, 4.6, 14.6 Hz, 1H) 
    129.4 6.96 (1H, s) 125.3 6.99 (s, 1H) 
    110.6 
 
111 
 
    128.3 
 
128.7 
 
    118.7 7.55 (1H, m) 119.1 7.58 (d, 7.8 Hz, 1H) 
    119.7 7.06 (1H, m) 120.1 7.09 (td,0.7, 7.2 Hz, 1H) 
    122.3 7.09 (1H, m) 122.7 7.14 (td, 1.0, 8.2 Hz, 1H) 
    112.3 7.25 (1H, m) 112.8 7.30 (dd, 7.3, 14.8 Hz, 1H) 
    137.8 
 
138.2 
 
    173.5 
 
*173.85 
 
   NH   8.06 (s, 1H) ** 
 
  NH   7.32 (obs, 1H) ** 
 
Pro
5
 α 60.9 4.34 (1H, m) 61.3 4.39 (dd, 5.9, 8.8 Hz, 1H ) 
  β 29.9 2.03 (1H, m) 30.2 2.38 (m, 1H) 
      1.40, (1H, m) 
 
1.44 (m, 1H) 
  γ 25.5 1.65 (1H, m) 26 2.11 (m, 1H) 
      1.40 (1H, m) 
 
1.95 (m, 1H) 
  δ 48.4 3.62 (1H, m) 48.9 3.61 (dd, 6.5, 12.7 Hz, 1H ) 
      3.28 (1H, m) 
 
3.32 (m, 1H) 
  CO 173.6 
 
*173.88 
 
Phe
6
 α 52.8 4.56 (1H, dd, 9.6, 4.0) 53.2 4.59 (dd, 3.8, 11.9 Hz, 1H) 
  β 37 2.62 (1H, m) 37.4 2.38 (m, 1H) 
      2.34 (1H, m) 
 
1.76 (m, 1H) 
  1 138.4 
 
138.8 
 
  2 and 6 130 7.12 (2H, m) 130.3 7.16 (d, 7.6 Hz, 2H) 
  3 and 5 129 7.27 (2H, m) 129.4 7.30 (dd, 7.3, 14.8 Hz, 2H) 
  4 127.4 7.18, (1H, m) 127.8 7.22 (t, 7.2 Hz, 1H) 
  CO 172.5 
 
*173.1 
 
  NH   8.22 ** 
 
Pro
7
 α 62.6 3.94 (1H, m) 63 3.97 (t, 8.0 Hz, 1H) 
  β 30.1 2.0 (1H, m) 30.5 2.03 (m, 1H) 
      1.78 (1H, m) 
 
1.84 (m, 1H) 
  γ 25.2 1.64 (1H, m) 25.8 1.70 (m, 1H) 
33 
 
      1.39 (1H, m) 
 
1.44 (m, 1H) 
  δ 48.4 3.96 (1H, m) 48.9 4.00 (m, 1H) 
    
 
3.55 (1H, m) 
 
3.73 (m, 1H) 
  CO 173.2 
 
*173.3 
 
Leu
8
 α 55 3.66 (1H, m) 55.4 3.69 (dd, 4.1, 11.6 Hz, 1H ) 
  β 36 2.34 (1H, m) 36.5 2.65 (t, 13.3 Hz, 1H ) 
    
 
1.72 (1H, m) 
 
2.36 (m, 1H) 
  γ 26 1.52 (1H, m) 26.4 1.54 (m, 1H) 
  δ1CH3 23.5 0.91 (3H, d,6.8) 23.8 0.91 (d, 6.6 Hz, 3H) 
  δ2CH3 20.8 0.89 (3H, d, 6.8) 20.7 0.87 (d, 6.7 Hz, 3H) 
  CO 173.5 
 
*173.95 
 
      
  NH   8.78 (d, 8.4 Hz, 1H) ** 
 
Note: * Overlapping carbonyl signals (171-174 ppm), ** NH signals were not detected   
 
Interestingly, the original paper by Tabudravu et al 
[20]
 describing the isolation and structure elucidation of 
axinellin C showed the detection of all the NH protons in CD3OD. In my study, the measurement of 
1
H NMR 
in CD3OD did not detect NH protons because of exchange. However, the amino acid residues and the peptide 
sequence determined in this study match the known compound.  
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2.4.4 Structure Elucidation of Compound D 
 
Compound D was afforded as a colorless oil. The MALDI-TOF MS showed a pseudomolecular ion peak 
at m/z 878.51 [M+H]
+
. The molecular formula was determined as C49H63N7O8 based on the high resolution 
ESI/MS. The infrared spectroscopy absorptions at 3683, 3020, 1518, 1206, and 793 cm
-1
 suggested the 
presence of amino, hydroxyl, and amide carbonyl groups. 
The 
1
H NMR spectrum (Figure 24) revealed the presence of aliphatic, alpha, and aromatic protons. A very 
distinct aromatic proton signal (6.76 ppm, doublet, 2H) indicated the presence of a phenolic group. A 
detailed analysis of 1D and 2D NMR data revealed the presence of seven amino acid residues: a pair of 
phenylalanine (Phe), proline (Pro), isoleucine (Ile), and a single tyrosine (Tyr) groups. The 
13
C NMR 
spectrum also revealed the presence of aliphatic, alpha, aromatic, and an overllaping seven carbonyl signals 
due to the presence of duplicate amino acid residues (Figure 25). Compound D was identified as a cyclic 
heptapeptide based on the molecular formula and constituent amino acids. All the protons were all assigned 
to each partial structure with the use of 1D and 2D NMR data analysis (Table 5). Also the five NH were 
assigned to each amino acids based on proton spectra in DMSO-d6. 
 
 
 
Figure 24. 
1
H NMR spectrum of compound D (600 MHz, CD3OD) 
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A doublet of methyl signal at 0.95 ppm (6H) and a triplet methyl signal at 0.85 ppm (6H) corresponded to 
a pair of isoleucine. Similarly, a doublet signals of aromatic protons at 6.75 ppm (2H), 7.23 ppm (2H), 7.17 
ppm (2H), 7.16 ppm (2H), and triplets at 7.28 and 7.27 ppm (2H each) and 7.30 and 7.31 ppm (1H each) 
reveals the presence of 3 aromatic rings. Two of the aromatic rings were identified as phenylalanine and 
other as a tyrosine. The 
13
C spectrum showed overlapping carbonyl signals (171.61-174.52 ppm) and 
therefore carbonyl carbons could not be properly assigned to each amino acid. It was also impossible to 
deduce the connectivity of the amino acids based on HMBC. The two proline-containing cyclic heptapeptide 
structures satisfied the 22 degrees of unsaturation, implied by the molecular formula.    
 
 
 
Figure 25. 
13
C NMR spectrum of compound D (150 MHz, CD3OD) 
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Table 5. NMR data for compound D in CD3OD and DMSO-d6 
 
Residues Position CD3OD DMSO-d6 
13
C 
1
H 
1
H 
Tyr
1
 NH   7.20 (1H, d, 4.7) 
 α 59.8 (d) 3.84 (1H, dd, 12.0, 4.3) 4.07 (1H, ddd, 9.8, 4.7, 2.6) 
 β 38.4 (t) 3.55 (1H, dd, 13.4, 12.0) 3.09 (1H, dd, 13.1, 2.6) 
   3.34 (1H, dd, 13.4, 4.3) 2.67 (1H, dd, 13.1, 9.8) 
 1 128.6 (s)   
 2/6 132.3 (d) 7.23 (2H, d, 8.9) 7.19 (2H, d, 8.5) 
 3/5 116.1(d) 6.75 (2H, d, 8.9) 6.70 (2H, d, 8.5) 
 4 157.4 (s)   
 CO 174.5 (s)   
 OH   8.54 (1H, s) 
Ile
2/5
 NH   7.34 (1H, d, 10.4) 
 α 57.2 (d) 4.28 (1H, d, 10.7) 4.19 (1H, dd, 10.7, 10.4) 
 β 38.1 (d) 2.13 (1H, m) 1.46 (1H, m) 
 γ 25.9 (t) 1.59 (1H, m) 1.45 (1H, m) 
   1.18 (1H, m) 1.10 (1H, m) 
 γ' 16.0 (q) 0.95 (3H, d, 6.7) 0.85 (3H, d, 6.7) 
 δ 10.4 (q) 0.89 (3H, t, 7.4) 0.78 (3H, t, 7.1) 
 CO 172.2-172.8 (s)   
 NH   8.45 (1H, d, 6.7) 
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Phe
3/7
 α 57.7 (d) 4.04 (1H, dd, 12.0, 4.6) 3.71 (1H, ddd, 11.4, 6.7, 6.6) 
 β 38.0 (t) 2.92 (1H, dd, 12,4, 4.6) 3.42 (1H, 13.1, 11.4) 
   2.80 (1H, dd, 12.4, 12.0) 3.25 (1H, 13.1, 6.6) 
 1 139.9 (s)   
 2/6 130.6 (d) 7.16 (2H, d, 7.6) 7.19 (2H, br d, 7.4) 
 3/5 129.5 (d) 7.27 (2H, t, 7.6) 7.27 (2H, br t, 7.4) 
 6 128.7 (d) 7.30 (1H, t, 7.6) 7.31 (1H, br t, 7.4) 
 CO 171.6 (s)   
Pro
4/6
 α 62.7 (d) 3.88 (1H, dd, 8.3, 7.7) 3.88 (1H, m) 
 β 30.5 (t) 1.88 (1H, m) 1.78 (1H, m) 
   1.76 (1H, m) 1.67 (1H, m) 
 γ 26.1 (t) 2.07 (1H, m) 2.00 (1H, m) 
   1.82 (1H, m) 1.73 (1H, m) 
 δ 49.0 (t) 4.41 (1H, m) 4.26 (1H, m) 
   3.60 (1H, dt, 9.1, 6.4) 3.57 (1H, m) 
 CO 172.2-172.8 (s)   
Ile
5/2
 NH   9.41 (1H, d, 8.5) 
 α 61.4 (d) 4.38 (1H, d, 11.3) 4.22 (1H, dd, 11.0, 8.5) 
 β 36.2 (d) 1.58 (1H, m) 2.02 (1H, m) 
 γ 22.6 (t) 1.58 (1H, m)  1.45 (1H, m) 
   1.18 (1H, m) 1.10 (1H, m) 
 γ' 15.6 (q) 0.95  (3H, d, 6.7) 0.86 (3H, d, 6.7) 
 δ 10.1 (q) 0.87 (3H, t, 7.4) 0.79 (3H, t, 7.1) 
 CO 172.2-172.8 (s)   
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Pro
6/4
 α 62.5 (d) 3.31 (1H, m) 3.99 (1H, m) 
 β 31.2 (t) 2.01 (1H, m) 2.28 (1H, m) 
   1.72 (1H, m) 1.50 (1H, m) 
 γ 22.7 (t) 1.74 (1H, m) 1.95 (1H, m) 
   1.43 (1H, m) 1.59 (1H, m) 
 δ 47.4 (t) 3.41 (2H, dd, 10.3, 4.4) 3.30 (2H, m) 
 CO 172.2-172.8 (s)    
Phe
7/3
 NH   8.77 (1H, br s) 
 α 56.2 (d) 4.18 (1H, dd, 8.9, 3.4) 4.01 (1H, br dd, 11.6, 4.6) 
 β 35.3 (t) 3.19 (1H, dd, 13.3, 3.4) 2.89 (1H, dd, 12.4, 4.6) 
   2.90 (1H, dd, 13.3, 8.9) 2.63 (1H, dd, 12.4, 11.6) 
 1 136.0 (s)   
 2/6 130.6 (d) 7.17 (2H, t, 7.6) 7.13 (2H, br d, 7.4) 
 3/5 130.8 (d) 7.27 (2H, t, 7.6) 7.27 (2H, br t, 7.4) 
 4 128.6 (d) 7.31 (1H, t, 7.6) 7.31 (1H, br t, 7.4) 
 CO 172.2-172.8 (s)   
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The NOE experiments were performed to identify the correlation between the neighbouring amino acid 
residues to identify the connectivity of the amino acids. In the NOE analysis five key cross peaks between the 
amino acid residues, Tyr
1
-Hα/Phe7-NH, Ile2-NH/Phe3-NH, Phe3-NH/Pro4-Hα, Pro4-Hα/Ile5-Hα and 
Ile-
5
-NH/Pro
6
-Hα were observed (Figure 26). This data enabled to construct two partial structures, 
Phe
3
-Pro
4
-Ile
5
-Pro
6
 and Phe
7
-Tyr
1
-Ile
2
.    
 
 
 
Figure 26. Planar structure of compound D established by NOE experiment 
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Figure 27. MALDI-TOF MS/MS of compound D 
 
By analyzing the MALDI-TOF MS (Figure 27) three fragmentation pathways were identified (Figure 28 
and 29). The first fragmentation pathway (sequence 1 in Figure 28 and 29) started with the opening of the 
macro cycle at the Pro
4
 amide bond and loss of Ile
5
 left m/z 765 (Pro
6
-Phe
7
-Tyr
1
-Ile
2
-Phe
3
-Pro
4
), loss of Pro
6
 
leaves m/z 668 (Phe
7
-Tyr
1
-Ile
2
-Phe
3
-Pro
4
), the loss of Phe
7
 left m/z 521 (Tyr
1
-Ile
2
-Phe
3
-Pro
4
), the loss of Tyr
1
 
left m/z 358 (Ile
2
-Phe
3
-Pro
4
) and finally the loss of Ile
2
 left m/z 245 (Phe
3
-Pro
4
). The second fragmentation 
pathway through the ring opening at amide bond of Pro
6
 and the loss of Phe
7
 left m/z731 
(Tyr
1
-Ile
2
-Phe
3
-Pro
4
-Ile
5
-Pro
6
), followed by loss of Tyr
1
 which left m/z 568 (Ile
2
-Phe
3
-Pro
4
-Ile
5
-Pro
6
), and 
loss of Ile
2
 left m/z 455 (Phe
3
-Pro
4
-Ile
5
-Pro
6
), loss of Phe
3
 left m/z 308 (Pro
4
-Ile
5
-Pro
6
), loss of Pro
4
 left m/z 
211 (Ile
5
-Pro
6
). The third sequence showed ring opening at amide bond Phe
7
 and Tyr
1
 and the subsequent 
loss of Phe
7
 left m/z 731 (Pro
6
-Ile
5
-Pro
4
-Phe
3
-Ile
2
-Tyr
1
) followed by loss of Pro
6
-Ile
5
 left m/z 520 
(Pro
4
-Phe
3
-Ile
2
-Tyr
1
), and the loss of Pro
4
 left m/z 424 (Phe
3
-Ile
2
-Tyr
1
). 
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Figure 28. Identification of peptide sequences by MALDI-TOF MS/MS 
 
Three fragmentation patterns were identified (Figure 28) from which two of the fragmentation patterns 
were identified as major peptide sequence while the third fragmentation pattern was identified as a minor 
peptide sequence. The sequences 1 and 2 were identified as major peptide sequence that covers the whole 
structure of compound D. Since the proline residues are more basic than the other amino acid residues, it was 
expected that the protonation and the initial fragmentation will occur from the N-terminus of the proline 
residues.  In the two major sequences the two proline residues were found at the N-terminus which proved 
that the protonation and the initial fragmentation have occurred as expected.  
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Figure 29. Determination of peptide sequence by MS/MS analysis 
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Three major peptide sequences, Ile
5
-Pro
6
-Phe
7
-Tyr
1
-Ile
2
, Phe
7
-Tyr
1
-Ile
2
-Phe
3
-Pro
4
, and 
Pro
4
-(Ile
5
-Pro
6
)-Phe
7
, were identified via the analysis of MALDI-TOF MS/MS fragmentation pattern of 
compound D, where Pro
4
 and Pro
6
 were observed at the N-terminus of the two of major peptide sequences 
which suggested a proline-effect.
[21]
 Usually, protonation of amide nitrogen weakens the amide bond and the 
carbon atom of the protonated amide group is attacked by nearby electron-rich groups resulting in a 
protonated linear peptide to make way for fragmentation. Because the proline is more basic, the amide of 
proline is predominantly protonated and cleaved. As a result, the planar structure was established as 
cyclo[Tyr
1–Ile2–Phe3–Pro4–Ile5–Pro6–Phe7] (Figure 30). The data base search returns no results, unlike 
compounds B and C. Therefore, Compound D was identified as new cyclic peptide and was named as 
stylissatin A.  
   
 
 
Figure 30. The planer structure of stylissatin A 
 
To establish the absolute stereochemistry of the stylissatin A Marfey’s method [22] was utilized (Figure 31). 
Stylissatin A (1 mg) was hydrolyzed with aq. 6 M HCl and derivatized with 
1-fluoro-2,4-dinitrophenyl-5-L-alanine amide (Marfey’s reagent). The dinitrophenyl-L-alanine amide 
derivatives were injected and analyzed with reverse phase HPLC [Deveosil ODS-HG-5 (ϕ 4.6 x 250 mm), 1 
mL/min, 30–40% aq. acetonitrile (MeCN) with 0.1% trifluoroacetic acid (TFA) (linear gradient for 60 min), 
25 
o
C, UV 340 nm]. Retention times of the authentic samples for L-Pro, 13.9 min; D-Pro, 16.3 min; L-Tyr, 
18.2 min; D-Tyr, 22.0 min; L-Ile, 38.9 min; D-Ile, 59.3 min; L-Phe, 43.9 min; D-Phe, 59.3 min were observed. 
The retention times of the test sample (hydrolysate) were observed for L-Pro, 13.9 min; L-Tyr, 18.2 min; 
L-Ile, 38.9 min; L-Phe, 43.9 min, and no peaks of D-amino acid derivative were detected. Therefore, from 
this analysis, it was determined that the entire amino acid residues have L-configuration and the absolute 
structure was also established (Figure 32).  
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Figure 31. Chromatogram of the retention time of derivatized amino acid residues  
 
 
 
Figure 32. The absolute stereostructure of stylissatin A 
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2.5 Summary 
 
Bioassay-guided isolation of the methanolic extract of the marine sponge Stylissa massa resulted in the 
identification of a novel cyclic peptide stylissatin A (1) including three known compounds (axinellin C, 
axinastatin 1, and 4,5-dibromopyrole-2-carboxylic acid methyl ester). The chemical structures of the 
compounds were elucidated using 1D and 2D NMR spectroscopy. The sequence of the amino acid residue 
and connectivity in the cyclic peptides was determined by MALDI-TOF MS/MS analysis. The absolute 
stereostructure of the stylissatin A was determined by Marfey’s method.    
Stylissatin A showed potent anti-inflammatory activity by suppressing the NO production in 
LPS-stimulated murine RAW264.7 macrophage cells while the known compound exhibited weak activity. 
The known compounds were previously isolated using different bioassays and were known to be active 
against different diseases. The axinastatin 1 was known to be active against leukemia cancer while the 
bioactivity of 4,5-dibromopyrrole carboxylic methyl ester was determined as inactive against plasmodium 
(malaria). The bioactivity of axinellin C in cancel cell line was inactive though the crude extract from which 
it was isolated showed activity against cancer cells.  
In this current study the identification of the potent anti-iNOS activity of these compounds was new and 
the result is promising. Further biological studies would be conducted as a follow up study in the near future 
to identify the mode of actions against inflammatory mediators such as tumor necrosis factor α (TNF-α) and 
cyclooxygenase 2 (COX-2).  
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2.6 Experimental 
2.6.1 General Experimental Procedure 
 
All chemicals were obtained commercially and used without further purification unless otherwise noted. 
Organic solvents and reagents for moisture-sensitive reactions were distilled by standard procedure. 
Anhydrous dichloromethane (CH2Cl2), tetrahydrofuran (THF), and N,N-dimethylformamide (DMF) were 
obtained commercially. Solvents for RP-HPLC were purchased as HPLC grade and used without further 
purification. Column chromatography was performed using silica gel BW-820MH or FL60D (75–200 or 
45–75 mm, Fuji Silysia Co., Aichi, Japan) or a Yamazen preparative silica gel (40 μm). All 
moisture-sensitive reactions were performed under an atmosphere of argon or nitrogen. Merck precoated 
silica gel 60 F254 plates were used for thin layer chromatography (TLC). 
1
H and 
13
C nuclear magnetic 
resonance (NMR) spectra were recorded on a Bruker Biospin AVANCE 600 spectrometer (600 MHz for 
1
H 
and 150 MHz for 
13
C). Chemical shifts were reported in parts per million (ppm) with coupling constants (J) 
in hertz relative to the solvent peaks, δH 3.31 (residual MeOD), δC 49.0 for CD3OD, δH 2.50 (residual 
Me2SO), and δC 39.5 for DMSO-d6, respectively. Optical rotations were measured with a JASCO DIP-1000 
polarimeter using the sodium D line. Infrared (IR) spectra were recorded on a JASCO FT/IR-4100 
spectrometer and reported in wavenumbers (cm
−1
). High-resolution electrospray ionization mass spectra 
(HR-ESIMS) were measured on a QSTAR Pulsar i spectrometer (Applied Biosystems) or an AccuTOF CS 
spectrometer (JEOL). Analytical RP-HPLC was acquired on a Shimazu Prominence HPLC System using an 
analytical column [Develosil ODS-HG-5 (ɸ 4.6 × 250 mm), Nomura Chemical Co., Aichi, Japan]. 
Preparative RP-HPLC was performed on a JASCO PU-2089i using a preparative column [Develosil 
ODS-HG-5 ɸ 20 × 250 mm)]. The following abbreviations are used to designate the multiplicities: s = 
singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of 
doublets, m = multiplet.  
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2.6.2 Animal Material 
 
The marine sponge Stylissa massa was collected by hand using SCUBA apparatus at a depth of 15-25 m in 
the ocean off the coast of Loloata island, Papua New Guinea, and was kept frozen until use. Some part of the 
specimen was deposited at the Laboratory of Pharmacology, School of Medicine and Health Sciences, 
Taurama Campus, University of Papua New Guinea. 
 
2.6.3 Isolation 
 
The orange marine sponge Stylissa massa (840 g, wet wt.), was blended with a food blender and extracted 
with 80% aq. MeOH. The methanolic extract was partitioned with ethyl acetate and H2O, and the EtOAc 
layer was further partitioned with n-hexane and 90% aq. MeOH. The MeOH layer was concentrated and 
partitioned further with CH2Cl2 and 60% aq. MeOH. The CH2Cl2 layer (Fr. 2, 685 mg) was separated into 
seven fractions by SiO2 column using CHCl3/MeOH (49/1 → 0/1) as solvents. Fr. 2-1 (167 mg) was further 
separated using preparative HPLC (SiO2) using n-hexane/EtOAc  (7/3 → 0/1) to give 15 fractions. Fr. 2-1-3 
(8 mg) was further separated by reversed phase HPLC (ODS-HG-5) in 75% aq. MeOH to give 4,5- 
dibromopyrrole-2-carboxylic acid methyl ester (A) 10 (1.0 mg). Fr. 2-3 (74.6 mg) was further separated into 
seven fractions by preparative HPLC (SiO2) using CHCl3/MeOH (9/1 → 0/1) as solvents. Fr. 2-3-1 (30 mg) 
was further separated by reversed phase HPLC (ODS-HG-5) in 75% aq. MeOH to afford axinastatin 1 (B) 
(5.0 mg), axinellin C (C) (3.6 mg), and stylissatin A (D) (3.0 mg). 
4,5-dibromopyrrole-2-carboxylic acid methyl ester (A): off-white solid; IR (CHCl3) 3683, 3431, 3019, 
2400, 1706, 1219, 792, 628; 
1
H and 
13
C NMR (Table 2); HR-EI-MS m/z 282.94 [M] (calcd for C6H5NOBr2), 
(△-0.7 mmu). 
Axinastatin 1 (B): off-white solid; [α]25D −19.6 (c 0.33, MeOH); IR (CHCl3) 3327, 3019, 2400, 1654, 1224, 
785 cm
-1
; 
1
H and 
13
C NMR (Table 3); HRMS (ESI) m/z 753.418 [M+H]
+
 (calcd for C50H57N9O9 [M+H]
+
,         
(△ –5.8 mmu) 
Axinellin C (C): colorless oil; [α]25D −17.3 (c 0.25, MeOH); IR (CHCl3) 3478, 2958, 2359, 1652, 1242, 775 
cm-
1
,; 
1
H and 
13
C NMR (Table 4); HRMS (ESI) m/z 938.650 [M+H]
+
 (calcd for C38H70N8O8 [M+H]
+
,          
(△ –1.3 mmu). 
Stylissatin A (D): colorless oil; [α]D
25
 −27 (c 0.11, MeOH); IR (CHCl3) 3683, 3400, 3019, 2400, 1706, 1219, 
791, 628 cm
-1
; 
1
H and 
13
C NMR (Table 5); HRMS (ESI) m/z 900.4618 [M+Na]
+
 (calcd for C49H63N7NaO8 
[M+Na]
+
, (△ –1.8 mmu).  
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2.6.4 Acid Hydrolysis  
 
  
 
                  Scheme 4. Hydrolysis of stylissatin A 
 
Solution of stylissatin A (1 mg) was pipetted into the 5 mL hydrolysis tube (Scheme 4). To the solution 
was added 6 N aq. HCl (0.2 mL) and the screw cap was tightly fixed to the tube. The tube was connected to a 
three-way cock that was connected to a vacuum source and nitrogen. As much as possible, air inside the tube 
was completely removed by freeze-thawing process and heated for 24 h at 110°C. After cooling, the solution 
was concentrated to dryness. The hydrolysate was dissolved with HPLC grade water and concentrated (0.5 
mL x 3) to completely remove the acid.  
The concentrated hydrolysate was dissolved with HPLC grade water (50 μL) and to it were added 1 M sat. 
NaHCO3 (80 μL) and 100 μL of 1% 1-fluoro-2-4-dinitrophenyl-5-L-alanine amide (FDAA, Marfey’s 
reagent) (1 mg, 3.6 μmol) in acetone and the mixture was heated at 40 oC for 2 h with frequent mixing. The 
mixture was cooled to room temperature and dissolved in 2 M aq. HCl (20 μL), and concentrated in 
desiccator over sodium hydroxide (NaOH) pellets for 12 h.         
 
 
 
 
 
49 
 
2.6.5 Amino Acid Derivatization 
 
 
 
Scheme 5. Derivatization of amino acid wih Marfey’s reagent 
 
The authentic samples (D- and L- isomers of Pro, Ile, Phe, and Tyr) were derivatized with Marfey’s 
reagent (N-(2,4-Dinitro-5-fluorophenyl)-L-alaninamide (FDAA) (Scheme 5). After cooling to room 
temperature, 2 M aq. HCl (20 uL) was added to the mixture and dried in a vacuum desiccator over NaOH 
pellets for 12 h. The residues were then dissolved in DMSO (0.5 ml). DMSO solution (2.5 μL) was made up 
to 5 μL with HPLC grade acetonitrile (2.5 μL) and injected and analyzed with reverse phase HPLC [Deveosil 
ODS-HG-5 (ϕ 4.6 x 250 mm), 1 mL/min, 40–60% aq. MeCN with 0.1% TFA (linear gradient for 60 min), 25 
o
C, UV 340 nm]. Retention times of the authentic samples for L-Pro, 13.9 min; D-Pro, 16.3 min; L-Tyr, 18.2 
min; D-Tyr, 22.0 min; L-Ile, 38.9 min; D-Ile, 59.3 min; L-Phe, 43.9 min; D-Phe, 59.3 min were observed. The 
retention times of the test sample (hydrolysate) were observed for L-Pro, 13.9 min; L-Tyr, 18.2 min; L-Ile, 
38.9 min; L-Phe, 43.9 min, and no D-amino acid derivative peaks was detected. Therefore, from this analysis, 
it was determined that the entire amino acid residues have L-configuration and the absolute structure was 
also established. 
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2.7 Bioassay 
Materials and Methods  
 
2.7.1 Chemicals for Bioassay 
 
Lipopolysaccharide (LPS) (endotoxin from Escherichia coli, serotype 0127:B8) was purchased from Santa 
Cruz Biotech, (3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazo-lium bromide) (MTT) was obtained from 
Wako, and other chemicals were purchased from Wako (Japan), containing Dulbecco’s Modification of Eagle 
Medium (DMEM, MP Biomedicals, Solon, Ohio, USA) and .05% trypsin−0.53% EDTA from Nakalai 
Tesque Inc., Kyoto, Japan. 
 
2.7.2 Cell Culture  
 
A murine RAW264.7 macrophage cell line (ATCC
®
 TIB-71
™
) was purchased from American Type 
Culture Collection (ATCC), 10801 University Boulevard Manasas, Va 20110 USA. Cells were cultured in 
plastic dishes/vials containing Dulbecco’s Modification of Eagle’s Medium (DMEM) (MP Biomedicals, 
Solon, Ohio, USA) supplemented with 10% fetal bovine serum, L-glutamine and sodium bicarbonate in a 
CO2 incubator (5% CO2 in air) at 37 °C and sub-cultured every 3 days at 75% confluent using 0.05% 
trypsin−0.53% EDTA in Ca2+, Mg2+ free phosphate-buffered saline (DPBS). 
 
2.7.3 NO Inhibitory Assay 
 
The production of nitric oxide was measured by Griess method according to the literature.
[23]
 NO 
production was indirectly assessed by measuring the nitrite (NO2
-
) levels in the cultured media and serum 
determined by a colorimetric method based on the Griess reaction. RAW264.7 cells were seeded at 1 × 10
6
 
cells/mL
 
in 96-well plates. After incubation overnight at 37 °C, samples (final concentration 0.6 – 200 µM in 
MeOH) and LPS (final concentration 1 µM, Santa Cruz Biotech, cat. No. sc3535) were simultaneously 
added. After the cells were incubated for 24 h, an aliquot of culture medium (100 µL) was mixed with an 
equal volume of Griess reagent (0.5% sulfanilamide, 0.05% N-naphthylethylenediamine hydrochloride in 5% 
phosphoric acid). Optical density at 540 nm was measured with a TECAN microplate reader (Infinite
®
 200 
Pro). All assays were performed in duplicate to confirm reproducibility.   
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2.7.4 Cytotoxicity Assay 
 
The cytotoxicity of samples was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) method. After the aliquot of culture medium was removed for NO production inhibitory 
assay as mentioned above, 1.4 mg/mL MTT solution in PBS (50 µL) was added to the cells. After 4 h, the 
culture medium was removed and the formazan product was dissolved in DMSO (150 μL). Optical density at 
540 nm was measured similarly as above.  
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Chapter 3. Solution Phase Synthesis of Stylissatin A 
3.1 Introduction 
 
Cyclic peptides and their derivatives continue to attract the attention of synthetic chemists and biologists 
alike. Apart from the occurrence of a variety of naturally occurring bioactive metabolites, cyclic peptides are 
often more stable in vivo than their linear peptides and often represented as promising drug candidates. 
Several cyclic peptides have been isolated 
[1]
 and synthesized (Figure 33).
[2]
  
Cyclosporin A, one of the bioactive cyclic peptides, was isolated as a microbial metabolite. It is a 
reversible inhibitor of cytokines in T helper cells.
[3]
 It was isolated from the fungus Trichoderma 
polysporum Rifai 
[4]
 and its absolute structure was confirmed by Kessler’s group [5] and its total synthesis was 
reported by Wenger.
[6]
 Gramicidin S is a cationic cyclic peptide produced by Bacillus brevis, and exhibits 
wide spectrum of activity against Gram negative and positive bacteria. A concise synthesis of gramicidin S 
was reported by Ohno and Wadhwani.
[7]
 Over the years many studies on isolation and synthesis of 
biologically active cyclic peptides have been reported. Cyclic peptides showed superior biological activity 
compared to the linear peptides due to their rigid and cyclic nature of their structures. Cyclic peptides have a 
wide spectrum of bioactivity including antibacterial, immunosuppressive, and anti-angiogenic. However, like 
many other compounds, synthesis of peptides, especially cyclic ones are met with obstacles. Due to the 
constrained structure of cyclic peptides, their synthesis often results in the loss configuration thus affecting 
the yield of target material.  
 
  
 
Figure 33. Cyclic peptide drugs 
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Cyclic peptides, which have constrained conformation have been of great interest as synthetic targets as 
well as both potential drug leads and the models for conformational analysis.
[8]
 Synthetic methods for cyclic 
peptides involve a partially or fully protected linear precursor which is then cyclized in organic solvents by 
solution or solid phase methods.
[9]
 Hence, in a typical peptide synthesis, construction of a peptide bond 
consists of two steps. The initial step requires activation of the carboxyl group of one amino acid, usually by 
a coupling reagent (Scheme 6). The second step involves a nucleophilic attack of the amino group of another 
amino acid derivative, usually an N-protected, on the carbon atom of the activated carboxylic group.
[10]
 
Therefore a peptide is formed as a result of an amide bond formation.   
 
 
 
 
Scheme 6. Formation of a peptide bond  
 
In peptide synthesis, like many other reactions, the formation of the amide bond with the preservation of 
stereogenic centre of the α-carbon is one of the vital reactions in organic synthesis and biochemistry. 
However, racemization is one of the major obstacles associated with peptide synthesis resulting in the loss of 
configuration leading to reduction of the yield of desired product.  
As shown in Schemes 7 and 8 there are two pathways for racemization to occur during the formation of 
peptide bond. The activation of the carboxylic acid A involves the conversion into the derivative B 
containing a leaving group X. The treatment of activated amino acid with base results in the abstraction of 
amide proton which transformed into C (Scheme 7). This transformation results in an increased acidity of 
alpha protons. The abstraction of amino acid α-proton from C gives rise to resonance stabilized carbanion D. 
Reprotonation of D on either side leads to the formation of racemized oxazolone E, which upon ring opening 
gives racemized product F. Racemization could occur without the formation of oxazolone (Scheme 8). 
Treatment of activated amino acid with base results in the abstraction of α-proton resulting in the 
intermediate G. Reprotonation of G can occur on either side thus forming racemized peptide H, and upon 
coupling with another amino acid or peptide results in racemized product I.   
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Scheme 7. Racemization of peptides via oxazolone formation 
 
 
 
Scheme 8. Racemization of peptides without oxazolone formation  
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There are simple approaches that can be applied to minimize racemization in peptide coupling. First is 
to place glycine (Gly) or proline (Pro) as C-terminal amino acid. Racemization doesn’t occur with glycine. In 
the case of Pro, racemization may occur but it’s very rare and cannot happen under normal condensation 
conditions. However, placing Pro as a C-terminal amino acid depends on the even distribution of this amino 
acid residue in the peptide segments. It is advisable to place amino acids, such as Pro, in the center of peptide 
segments to increase the solubility of the peptide segments. Another approach is to use coupling reagents and 
methods that prevent racemization.
[11]
       
  
 
 
Figure 34. Peptide coupling reagents 
 
Peptide coupling is a very important reaction in organic synthesis. It has significantly advanced with the 
development of new peptide coupling reagents. Several classes of coupling reagents have been developed 
including phosphonium, uronium, immmonium, carbodiimide, imidazolium, organophophorous, and acid 
halogenating reagents. Conventional peptide coupling reagents includes 
O-(benzotriazol-1-yl)- N,N,N',N' -tetramethyluronium hexafluorophosphate (HBTU), 
(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), and 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC·HCl) (Figure 34). These coupling 
reagents has have been successfully used to synthesize peptides with comparable yield.   
The uronium compound (HBTU) is one of the efficient peptide coupling reagents with little 
racemization.
[12]
 PyBOP, a halogeno-phosphonium compound, which is known to couple amino acids 
efficiently.  Coupling of peptides or amino acids in the presence of PyBOP is also rapid and sometimes 
reactions can be completed within an hour.  To avoid the racemization and side reactions that occur with 
carbodiimide reagents, PyBOP was one of the reagents developed to generate esters in situ. It is an excellent 
coupling reagent that is more advantageous than other phosphonium reagents and yields less noxious 
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by-products. Racemization is also minimum with PyBOP.
[13]
 The EDC·HCl is a carbodiimide compound that 
is commonly used to prepare amides, esters and acid anhydrides from carboxylic acids. However, 
carbodiimide activation of amino acid derivatives often causes a partial racemization of the amino acid.
[14]
  
 
 
 
Figure 35. DEPBT, an organophosphorus peptide coupling reagent  
 
The 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT), an organophosphorus peptide 
coupling reagent, is one of the effective coupling reagents for peptide synthesis in both solution and solid 
phases (Figure 35). It prevents epimerization during peptide bond formation.  It is very useful for coupling 
amino acids and peptides that are easily epimerized.  DEPBT has been also shown to be a superior reagent 
in head-to-tail cyclization of linear peptides.
[15]
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Scheme 9. Reaction mechanism of DEPBT 
[15]
 
 
A tertiary amine activates the protected amino acid to generate a carboxylate (Scheme 9). The carboxylate 
attacks the phosphorus atom of DEPBT resulting in a transient intermediate A. The intermediate A 
transforms into a stable activated ester B via the loss of diethyl phosphate. This strongly activated stable 
intermediate is attacked by an amine to form the amide product C. Interestingly, when using DEPBT as a 
coupling reagent, the hydroxy group of the amino acids (serine, threonine, and tyrosine) does not need to be 
protected. The side reaction caused by other coupling reagents was not observed in peptide couplings 
mediated by DEPBT.
[15a]
 
 
60 
 
 
 
Figure 36. Peptide coupling additives 
 
The reactivity of peptide coupling reagents can be enhanced by the addition of additives. The addition 
of coupling additives may also serve to reduce the racemization and speed up reaction. Active species can be 
captured using a hydroxylamine derivative to give the corresponding active esters. Many additives such as 
hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), and 
3-hydroxy,1,2,3-benzotriazin-4(3H)-one (HOOBt), have an OH in their structure (Figure 36) that can form 
active esters with the carboxylic acid. These additives and its urea byproduct are water-soluble so they can 
be easily removed by aqueous extraction.
[16]
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Scheme 10. Peptide coupling reaction furnished by additives 
 
The activated carboxylic acid is converted to acylisourea by reaction with carbadiimide (Scheme 10). The 
acylisourea is very susceptible to rearrangement and transforms into an unreactive N-acylurea. However, in 
the presence of additives such as HOAt, it is spontaneously converted to a reactive 1-hydroxybenzotriazole 
activated ester. This avoids formation of unreactive N-acylurea. 
The conventional methods for peptide cyclization have revolved around the use of organic reagents 
(coupling reagents and additives). However, the scope has been extended to include the use of non-organic 
additives, such as metal ions. Some peptides are known to act as ionophores in vivo and to form a very stable 
ion complexes with metal ions.
[17]
 Palladium and copper ions were some of the first examples of the use of 
metal ions to re-arrange a peptide for macrocyclization. Several alkali metals have been used to prepared 
cyclic peptides, which not only enhance cyclization but also improve the solubility of peptides. Alkali metal 
ions have been shown to enhance the head-to-tail cyclization of peptides via the tandem co-ordinations of 
amidic oxygen atoms along the peptide chain (Scheme 11).
[18, 19]
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Scheme 11. Peptide cyclization assisted by alkali metal ions 
 
In this Chapter, the synthesis of stylissatin A will be described. The coupling of amino acids and the linear 
peptides will be performed in the presence of DEPBT as a coupling reagent and diisopropylethylamine 
(DIPEA) as a base. The macrolactamization step will be investigated using various coupling reagents and 
additives that are mentioned.   
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3.2 Synthesis 
3.2.1 Synthetic Strategy for Stylissatin A 
 
The cyclic peptide stylissatin A (1) contains seven L-amino acid residues. The synthesis of stylissatin A 
was planned to be conduct in solution phase. It was envisioned that 1 would arise from the condensation of 
segments 1 (3) and 2 (4) followed by the macrolactamization of 2, after the deprotection. The two segments 
would be prepared via the coupling and elongation of commercially available Fmoc-protected amino acids (6, 
7, and 8), using isoleucine methyl ester hydrochloride salt (H-Ile-OMe･HCl) (5) as a common staring 
material (Scheme 12).  
 
Scheme 12. Restrosynthetic pathway for stylissatin A (1) 
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3.2.2 Synthesis of Segments 1 and 2 
 
The synthesis of stylissatin A (1) begun with the preparation of the common starting material 5. 
Commercially available L-isoleucine (H-Ile-OH) was converted to isoleucine methyl ester hydrochloride (5) 
in the presence of thionyl chloride (SOCl2) and methanol (MeOH) via esterification (Scheme 13). 
[20]
 With 
the starting material 5 in hand, the synthesis of segment 1 (3) was pursued. The isoleucine methyl ester 
hydrochloride (5) was coupled with Fmoc-L-Phe-OH (6) in the presence of 
3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT) as a condensation reagent and 
diisopropylethylamine (DIPEA) as a base in tetrahydrofuran (THF) at room temperature to afford protected 
dipeptide 11. The dipeptide was first treated with 20% piperidine in N,N-dimethylforamide (DMF) followed 
by coupling with Fmoc-L-Pro-OH (7) to afford segment 1 (3) as a white solid. 
  
 
 
Scheme 13. Synthesis of segment 1 (3) 
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The same scheme used to prepare segment 1 was applied in the preparation of segment 2. The common 
starting material 5 was coupled with 7 to afford a protected dipeptide 12 (Scheme 14). The Fmoc group was 
first cleaved from 12 followed by the coupling with 6 gave protected tripeptide 13. The tripeptide was treated 
with 20% piperidine in dry DMF followed by the coupling with Fmoc-L-Tyr(tBu)-OH (8) to afford segment 
2 (4) as a white solid.  
 
 
 
Scheme 14. Synthesis of segment 2 (4) 
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3.2.3 Segment Condensation 
 
The selective cleavage of an ester function without affecting the Fmoc protecting group on the amino 
group is an important strategy in peptide synthesis. The availability of simple and straightforward procedures 
that would allow the alternative deprotection of the carboxyl or α-amino functions with high 
chemoselectivity represents a challenging reaction in the synthesis of peptides, especially when the peptide 
chains are synthesized by a building-block approach.
[21]
 
The hydrolysis of the segment 1 (3) was examined in three conditions (Table 6). The hydrolysis of 3 with 
aluminum chloride and N,N-dimethylaniline  (AlCl3/DMA)
[22]
 in CH2Cl2 did not give carboxylic acid 14 but 
undesired product 15 (Entry 1). The hydrolysis of 3 with lithium hydroxide (LiOH)
[23] 
gave a reasonable 
yield of the target material 14 (Entry 2). Interestingly, the hydrolysis of 3 in the presence of trimethyltin 
hydroxide (Me3SnOH) in 1,2-dichloroethane (ClCH2CH2Cl)
[24]
 (Entry 3) resulted in the cleavage of methyl 
ester to give the desired product 14 in 64% yield (Entry 3). 
 
Table 6．Investigation of methyl ester hydrolysis condition  
 
 
Entry Reagents Solvent Time (h) Temp (
o
C) Yield (%) 
     14 15 
1 AlCl3/DMA CH2Cl2 6 reflux 0 83 
2 LiOH THF/H2O (2:1) 24 rt 42 0 
3 Me3SnOH ClCH2CH2Cl 8 78 64 0 
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Next, segment coupling was investigated (Scheme 15). The tetrapeptide 4 was treated with 20% piperidine 
in DMF at room temperature to obtain a crude free amine. The crude amine, without further purification, was 
coupled with caboxlic acid 14 by DEPBT and DIPEA at ambient temperature to afford protected 
heptapeptide 2.    
 
 
Scheme 15. Synthesis of linear heptapetide 2 
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3.2.4 Macrolactamization 
 
The hydrolysis of 2 was performed in the presence of Me3SnOH in 1,2-dichloroethane followed by the 
treatment with 20% piperidine in DMF to afford an intermediate 16 as a white solid (Scheme 16).  
  
 
 
Scheme 16. Preparation of intermediate 16 
 
With the intermediate 16 in hand, the important macrolactimization step was examined in EDC·HCl, 
PyBOP, HBTU, and DEPBT (Table 7). The entries 1 and 2 
[24]
 favored the formation of an epimer 
(D-allo-Ile
5
 analog) 9b while entries 3 and 4 
[25]
 favored the formation of target material 9a. Interestingly, the 
use of DEPBT (Entry 5) as a cyclization reagent in the presence DIPEA and an aqueous metal salt   
(NaCl) 
[19a, 26]
 in THF has proven to be superior over other conditions giving the target material in 61% yield.  
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Table 7. Macrolactimization of 16 
 
 
 
Entry Condition Solvent Time (h) Temp (
o 
C) Yield (%) 
     9a 9b 
1 EDC·HCl, HOOBt, Et3N DMF 64 rt 18 57 
2 PyBOP, HOBt DMF 64 rt 34 41 
3 HBTU, DIPEA DCM/DMF (5:1) 24 rt 37 12 
4 DEPBT, 4-EM DMF 48 rt 41 19 
5 DEPBT, NaCl, DIPEA DMF 24 rt 61 20 
DCM = Dichloromethane 
4-EM = 4-ethylporpholine  
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3.2.5 Completion of the Synthesis of Stylissatin A 
 
The tert-butyl ether in 9a was cleaved with 95% TFA in water to afford stylissatin A (1) in 85% yield 
(Scheme 17).  
 
 
Scheme 17. Completion of the synthesis of stylissatin A (1) 
 
Similarly, epimer 10 (D-allo-Ile
5
) was obtained after the cleavage of tert-butyl group of 9b in 87% yield 
(Scheme 18). 
 
 
 
Scheme 18. Completion of the synthesis of epimer 10 
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3.2.6 Elucidation of Structures  
 
Comparison of 
1
H NMR spectra of synthetic and the natural stylissatin A were in agreement (Figure 37). 
This confirmed the successful synthesis of stylissatin A (1) and the proposed chemical structure that were 
previously reported. In contrast, the 
1
H NMR spectrum of 10 was not identical with the spectrum of 1. The 
phenolic proton signals of 10 were resonating up-field at 6.60 ppm while those of 1 resonate downfield at 
6.70 ppm. The alpha protons of 10 were spread across 2.98-3.08, 3.40-3.75 and 4.27-4.36 ppm unlike those 
of 1. Significant differences in aliphatic protons were observed in the isoleucine moiety. The two triplets (3H 
each) of β-methyl of 10 resonating at 1.00 and 0.86 ppm while the two doublets (3 H each) of δ-methyl 
resonating at 0.93 and 0.62 ppm. On the other hand doublets of the β-methyl (6H) of 1 were overlapping at 
0.96 ppm while the triplets of δ-methyl (6H) were also overlapping at 0.90 ppm.    
 
 
 
Figure 37. 
1
H NMR spectra of synthetic and natural stylissatin A (1) and epimer 10 (600 MHz, CD3OD) 
Epimer 10 
 
Natural 1 
 
Synthetic 1 
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Similar to the 
1
H NMR spectrum, the 
13
C NMR spectrum of synthetic stylissatin A (1) was consistent with 
that of the natural product (Figure 38). The 
13
C NMR spectrum of 10, unlike the proton spectra, showed 
similar resonance pattern to that of 1 with minor differences. Comparing the two aromatic carbons at position 
1 of the two phenylalanine moieties, in 1 the two carbons resonates at 136.0 and 139.0 ppm in 1 while the 
two carbons resonate at 137.0 and 138.0 ppm in 10. A similar difference was observed in the chemical shifts 
of δ-methyl of isoleucine moieties. The δ-methyl carbons resonate at 19.01 and 19.90 ppm in 1 while signals 
at 20.30 and 21.0 ppm were observed for 10.   
          
 
 
Figure 38. 
13
C NMR spectra of synthetic and natural stylissatin A (1) and epimer 10 (CD3OD, 150 MHz) 
   
 
 
Synthetic 1 
 
Epimer 10 
 
Natural 1 
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3.3 Biological Evaluation of Synthetic Cyclic Peptides 
 
After the completion of the synthesis of stylissatin A (1), the NO-production inhibitory activity of 1, and 
its synthetic derivatives were investigated (Table 8). The amount of NO liberated in the culture medium was 
measured using the Griess method 
[27]
 while the cytotoxicity was measured by MTT assay.
[28]
 The natural and 
synthetic samples of stylissatin A were observed to exhibited comparable inhibitory effects on nitric oxide 
production in LPS-stimulated RAW264.7 cells. In addition, synthetic 1 exhibited no cytotoxicity even at 
highest concentration (200 μM), while natural 1 showed slight activity (refer to Chapter 2). This difference in 
cytotoxicity might have been due to the presence of trace amount of cytotoxic impurity in natural product. 
 
Table 8. Biological evaluation of synthetic products 
 
Compounds NO inhibition Cell viability Selectivity index 
 (EC50, μM) (IC50, μM) (IC50/EC50) 
1 73 >200 >2.7 
10 140 >200 >1.4 
9a 12 >200 >17 
9b 13 >200 >16 
 
The D-allo-Ile
5
 isomer 10 exhibited weaker activity at inhibiting NO production than 1. Interestingly, the 
protection of hydroxy group of tyrosine moiety as a tert-butyl ether as in 9a and 9b resulted in an enhanced 
activity, 6 -10 times more potent than 1 and 10, respectively. The applicability of other hydroxy protecting 
groups in reducing NO formation in the current study is yet to be clarified. Still, these results indicated that 
the tyrosine hydroxy group of in 1 could be readily modified to develop suitable chemical probes to 
investigate the mode of actions of stylissatin A and its derivatives. 
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3.4 Summary  
 
The first synthesis of a naturally occurring cyclic heptapeptide stylissatin A (1) (cyclo 
[L-Ile-L-Pro-L-Ple-L-Tyr-L-Ile-L-Phe-L-Pro]), was achieved via solution-phase peptide synthesis. The amino 
acid coupling and peptide elongation of the linear heptapeptide unit and its subsequent cyclization gave the 
cyclic peptide 1, identical in all aspects to the naturally occurring compound.  
The coupling reagent DEPBT was proven to be an efficient coupling reagent as no racemization was 
observed throughout the coupling and elongation of the peptides in this study. However, epimerization still 
occurred during the macrolactamization as a result of steric hindrance of the C-terminus isoleucine and have 
affected the final yield of 1. As for macrolactamization, the use of DEPBT in the presence of DIPEA and 
sodium ion (Na
+
) proved superior over other cyclization reagents to give the best yield (61%). This result 
proved that alkali metal ions enhanced the head-to-tail cyclization of a peptide through the tandem 
co-ordinations of amidic oxygen atoms along the peptide chain. 
The subsequent biological studies of the synthetic products have revealed the inhibitory activity of NO 
production. An enhanced activity in the reduction of NO production in LPS-stimulated murine RAW264.7 
macrophage cells was observed by the protection of tyrosine hydroxy group with tert-butyl group in 1. 
Further structure-activity-relationship studies and elucidation of the mode of actions for stylissatin A and its 
derivatives will be further investigated. 
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3.5 Experimental Section 
General Materials and Methods for Organic Synthesis  
 
All chemicals were obtained commercially unless otherwise noted. Organic solvents and reagents for 
moisture-sensitive reactions were distilled by standard procedure. Anhydrous dichloromethane (CH2Cl2), 
tetrahydrofuran (THF), and N,N-dimethylformamide (DMF) were obtained commercially. Solvents for 
RP-HPLC were purchased as HPLC grade and used without further purification. Column chromatography 
was performed using silica gel BW-820MH or FL60D (75–200 or 45–75 μm, Fuji Silysia Co., Aichi, Japan) 
or a Yamazen preparative silica gel (40 μm). All moisture-sensitive reactions were performed under an 
atmosphere of argon or nitrogen. Merck precoated silica gel 60 F254 plates were used for thin layer 
chromatography (TLC). 
1
H and 
13
C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker 
Biospin AVANCE 600 spectrometer (600 MHz for 
1
H and 150 MHz for 
13
C). Chemical shifts were reported 
in parts per million (ppm) with coupling constants (J) in hertz relative to the solvent peaks, δH 3.31 (residual 
CHD2OD), δC 49.0 for CD3OD, δH 2.50 (residual Me2SO), and δC 39.5 for DMSO-d6, respectively. Optical 
rotations were measured with a JASCO DIP-1000 polarimeter using the sodium D line. Infrared (IR) spectra 
were recorded on a JASCO FT/IR-4100 spectrometer and reported in wavenumbers (cm
−1
). High-resolution 
electrospray ionization mass spectra (HR-ESIMS) were measured on a QSTAR Pulsar i spectrometer 
(Applied Biosystems) or an AccuTOF CS spectrometer (JEOL). Analytical RP-HPLC spectra were acquired 
on a Shimazu Prominence HPLC System using an analytical column [Develosil ODS-HG-5 (ɸ 4.6 × 250 
mm), Nomura Chemical Co., Aichi, Japan]. Preparative RP-HPLC was performed on a JASCO PU-2089i 
using a preparative column [Develosil ODS-HG-5 ɸ 20 × 250 mm)]. The following abbreviations are used to 
designate the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, dd= doublet of doublets, dt= 
doublet of triplets, td= triplet of doublets, m = multiplet. 
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3.5.1 Synthesis of isoleucine methyl ester hydrochloride (H-Ile-OMe·HCl) (5) 
 
 
 
To a stirring methanol (MeOH) (10 mL) cooled to -10 
o 
C and was added thionyl chloride (SOCl2) (7 mL, 
59 mmol) dropwise. To the mixture was added L-isoleucine (H-Ile-OH) (5.75 g, 44 mmol). The resulting 
mixture was stirred at -10 
o 
C to room temperature for 48 hours and concentrated. The crude material was 
dissolved in MeOH (5 mL) and concentrated three times to completely remove traces of thionyl chloride 
followed by crystallization in diethyl ether (Et2O) (6 mL). The crystallized product was separated with silica 
gel in open column chromatography (SiO2, 3 g) in chloroform/methanol (CHCl3/MeOH, 9/1 → 0/1) to afford 
5 (7.0 g, 39 mmol, 88% yield) as a white solid.  
 
Rf = 0.85 (CHCl3/MeOH = 2:1).  
m.p.: 97.5–99.5 ºC.  
[α]D
22
 +26 (c 1.0, CHCl3).  
1
H NMR (600 MHz, DMSO-d6) δ 8.70 (br s, 3H), 3.85 (d, J = 4.1 Hz, 1H), 3.71 (s, 3H), 1.95 (m, 1H), 1.44 
(qd, J = 7.3, 5.9 Hz, 1H), 1.25 (qd, J = 8.2, 7.4, Hz, 1H), 0.87 (d, J = 7.0 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ 169.1, 56.1, 52.5, 35.9, 25.4, 14.3, 11.5. 
IR (CHCl3) 2969, 1748, 1595, 1523, 1459, 1442, 1226, 1217, 1176, 1112, 1042, 1011, 962, 907, 876, 803, 
751, 721 cm
–1
. 
HRMS (ESI) m/z 146.1167 (calcd for C7H16NO2 [M+H]
+, ∆ –1.4 mmu).  
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3.5.2 Synthesis of Fmoc-L-Phe-L-Ile-OMe (11) 
 
 
 
To a solution of H-Ile-OMe.HCl (5) (2.6 g, 18 mmol) in dry tetrahydrofuran (THF) (10 mL) was added 6 
(Fmoc-L-Phe-OH, 7.2 g, 19 mmol). The resulting mixture was cooled to 0 
o
C while stirring.  
N,N-diisopropylethylamine (DIPEA) (3.0 mL, 23 mmol) and 
3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT) (7.0 g, 23 mmol) were added. The 
resulting mixture was allowed to stir at room temperature for 12 h. The crude mixture was diluted with ethyl 
acetate (20 mL) and washed with 1 M aq. HCl (6 mL x 3), saturated sodium hydrogen carbonate (NaHCO3) 
(6 mL x 3), and brine (6 mL x 3). The organic layer was dried with magnesium sulfate (MgSO4) overnight 
and concentrated. The crude solid material was separated with Yamazen silica gel middle pressure liquid 
chromatography (MPLC) in Hex/EtOAC (4/1 → 0/1) to afford dipeptide 11 (7.0 g, 14 mmol, 97%) as a 
white solid. 
  
Rf = 0.43 (hexane/EtOAc = 2:1).  
m.p.: 141.5–143.5 ºC.  
[α]D
22
 −0.80 (c 1.0, CHCl3). 
1
H NMR (600 MHz, DMSO-d6) δ 8.41 (d, J = 7.6 Hz, 1H), 8.26 (d, J = 8.0 Hz, 1H), 7.87 (d, J = 7.5 Hz, 2H), 
7.63 (dd, J = 12.8, 7.6 Hz, 2H), 7.44–7.37 (m, 2H), 7.35–7.23 (m, 6H), 7.19 (t, J = 7.3 Hz, 1H), 4.39 (m, 1H), 
4.25 (t, J = 7.1 Hz, 1H), 4.19–4.10 (m, 3H), 3.62 (s, 3H), 2.97 (dd, J = 13.8, 3.7 Hz, 1H), 2.77 (dd, J = 13.4, 
11.0 Hz, 1H), 1.80 (m, 1H), 1.42 (m, 1H), 1.20 (m, 1H), 0.85 (d, J = 6.8 Hz, 3H), 0.84 (t, J = 7.7 Hz, 3H). 
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13
C NMR (150 MHz, DMSO-d6) δ 171.9, 171.8, 155.7, 143.7 (2C), 140.6 (2C), 138.0, 129.2 (2C), 128.0 
(2C), 127.6 (2C), 127.0 (2C), 126.2, 125.3 (2C), 120.0 (2C), 65.6, 56.4, 55.6, 51.6, 46.5, 37.3, 36.3, 24.8, 
15.4, 11.1.  
IR (CHCl3) 3422, 3027, 3013, 2967, 1736, 1680, 1498, 1451, 1233, 1222, 1183, 1144, 1105, 1081, 1049, 
1033, 1008, 965, 788, 784, 701 cm
–1
.  
HRMS (ESI) m/z 537.2361 (calcd for C31H34N2NaO5 [M+Na]
+, ∆ –0.4 mmu).  
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3.5.3 Synthesis of Fmoc-L-Pro-L-Phe-L-Ile-OMe (3)  
 
 
 
To a protected dipeptide 11 (7.0 g, 14 mmol) was added 20% piperidine in dry N,N-dimethylforamide 
(DMF) (12.0 mL). The solution was stirred for 1 h at room temperature and concentrated. The crude material 
partially separated with SiO2 column (4.0 g) in CHCl3/MeOH (9/1 → 0/1) to obtain a crude free amine. To a 
stirred solution of the crude amine in anhydrous THF (10 mL) was added 7 (Fmoc-L-Pro-OH, 2.2 g, 7.0 
mmol) and the resulting mixture was cooled to 0 
o
C while stirring. To the cooled mixture was added DIPEA 
(4.0 mL, 31 mmol) dropwise followed by the addition of DEPBT (7.0 g, 23 mmol). The resulting mixture 
was stirred at an ambient temperature for 16 h. The reaction mixture was diluted with EtOAc (20 mL) and 
washed with 1 M aq. HCl (5 mL x 3), saturated aq. NaHCO3 (5 mL x 3), brine (5 mL x 3), dried with MgSO4, 
and concentrated. The crude material was separated with silica-gel open column chromatography (SiO2, 2.0 
g) in CHCl3/MeOH (9/1 → 0/1) to afford tripeptide 3 (2.8 g, 4.6 mmol, 79%) as a white solid.   
Rf = 0.10 (hexane/EtOAc = 1:1) 
m.p.: 60.5–62.0 ºC  
[α]D
22
 −67 (c 1.0, CHCl3)  
1
H NMR (600 MHz, DMSO-d6) δ 8.26 (d, J = 7.9 Hz, 0.5H), 8.16 (d, J = 8.5 Hz, 0.5H), 8.00 (d, J = 7.0 Hz, 
0.5H), 7.98 (d, J = 6.9 Hz, 0.5H), 7.90 (d, J = 7.6 Hz, 1H), 7.88 (d, J = 7.3 Hz, 1H), 7.67–7.64 (m, 1H), 7.56 
(d, J = 7.5 Hz, 0.5H), 7.53 (d, J = 7.4 Hz, 0.5H), 7.44–7.39 (m, 2H), 7.37–7.27 (m, 2H), 7.23–7.13 (m, 3.5H), 
6.98 (t, J = 7.4 Hz, 1H), 6.90 (t, J = 7.4 Hz, 0.5H), 4.74 (m, 0.5H), 4.57 (m, 0.5H), 4.37–4.32 (m, 1H), 4.27 (t, 
J = 6.7 Hz, 0.5H), 4.23–4.10 (m, 2.5H), 3.92–3.85 (m, 1H), 3.61 (s, 1.5H), 3.57 (s, 1.5H), 3.47–3.37 (m, 1H), 
3.37–3.27 (m, 1H), 3.03 (dd, J = 14.0, 4.7 Hz, 0.5H), 2.96 (dd, J = 13.8, 4.1 Hz, 0.5H), 2.85–2.77 (m, 1H), 
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2.14 (m, 0.5H), 1.96 (m, 0.5H), 1.83–1.60 (m, 4H), 1.43–1.27 (m, 1H), 1.25–1.15 (m, 1H), 0.82 (d, J = 6.8 
Hz, 1.5H), 0.79 (t, J = 7.4 Hz, 1.5H), 0.75 (d, J = 7.0 Hz, 1.5H), 0.74 (t, J = 7.4 Hz, 1.5H).  
13
C NMR (150 MHz, DMSO-d6) δ 171.9 (0.5C), 171.6, 171.5 (0.5C), 171.4 (0.5C), 171.1 (0.5C), 154.3 
(0.5C), 153.9 (0.5C), 144.1 (0.5C), 143.8 (0.5C), 143.7 (0.5C), 143.4 (0.5C), 140.7, 140.6 (0.5C), 140.5 
(0.5C), 137.7 (0.5C), 137.6 (0.5C), 129.14, 129.07, 127.9, 127.7, 127.5, 127.13, 127.09, 126.1, 125.9 (0.5C), 
125.5 (0.5C), 125.1, 125.0, 120.1, 120.0, 66.9 (0.5C), 66.6 (0.5C), 59.9 (0.5C), 59.6 (0.5C), 56.4 (0.5C), 56.3 
(0.5C), 53.44 (0.5C), 53.40 (0.5C), 51.6, 47.1 (0.5C), 46.6 (0.5C), 46.5 (0.5C), 46.4 (0.5C), 37.3 (0.5C), 36.9 
(0.5C), 36.3 (0.5C), 36.2 (0.5C), 31.1 (0.5C), 29.6 (0.5C), 24.7 (0.5C), 24.6 (0.5C), 23.6 (0.5C), 22.7 (0.5C), 
15.3 (0.5C), 15.2 (0.5C), 10.9. 
IR (CHCl3) 3413, 3024, 3012, 2965, 1739, 1685, 1507, 1452, 1417, 1356, 1336, 1301, 1268, 1235, 1210, 
1191, 1149, 1122, 1090, 985, 702 cm
–1
. 
 HRMS (ESI) m/z 634.2880 (calcd for C36H41N3NaO6 [M+Na]
+, ∆ –1.3 mmu). 
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3.5.4 Synthesis of Fmoc-L-Pro-L-Phe-L-Ile-OH (14) 
 
 
 
To a solution of tripeptide 3 (97 mg, 0.16 mmol) in anhydrous 1,2-dichloroethane (6 mL) was added 
trimethyltin hydroxide (Me3SnOH) (88 mg, 0.49 mmol). The resulting mixture was stirred at 78 
o 
C for 8 h. 
The mixture was diluted with EtOAc (20 mL) and washed twice with 5% aq. HCl (6 mL x 2) and brine (6 
mL x 2). The crude organic layer was dried in MgSO4 overnight and concentrated. The crude material was 
separated with silica gel (SiO2, 3 g) in with CHCl3/MeOH (9/1 → 0/1) to afford carboxylic acid 14 (60.4 mg, 
0.1 mmol, 64%) as a light yellow solid.  
    
Rf = 0.28 (CHCl3/MeOH = 9:1). 
m.p.: 96.5–99.0 ºC. 
[α]D
22
 −24 (c 1.5, CHCl3). 
1
H NMR (600 MHz, DMSO-d6) δ 8.16 (d, J = 8.4 Hz, 0.5H), 8.05 (d, J = 7.9 Hz, 0.5H), 7.99 (d, J = 8.2 Hz, 
0.5H), 7.90 (d, J = 7.5 Hz, 1H), 7.87 (d, J = 7.4 Hz, 1H), 7.80 (d, J = 7.9 Hz, 0.5H), 7.66 (t, J = 6.4 Hz, 1H), 
7.56 (d, J = 7.4 Hz, 0.5H), 7.53 (d, J = 7.4 Hz, 0.5H), 7.45–7.37 (m, 2H), 7.37–7.26 (m, 2H), 7.25–7.13 (m, 
3.5H), 6.95 (t, J = 7.4 Hz, 1H), 6.87 (t, J = 7.3 Hz, 0.5H), 4.71 (m, 0.5H), 4.57 (m, 0.5H), 4.38–4.31 (m, 1H), 
4.26 (t, J = 6.8 Hz, 0.5H), 4.23–4.08 (m, 2.5H), 3.92–3.84 (m, 1H), 3.60–3.20 (m, 2H), 3.05 (dd, J = 13.9, 
4.1 Hz, 0.5H), 3.00 (dd, J = 13.8, 3.8 Hz, 0.5H), 2.87–2.78 (m, 1H), 2.15 (m, 0.5H), 1.96 (m, 0.5H), 
1.83–1.60 (m, 4H), 1.45–1.31 (m, 1H), 1.25–1.06 (m, 1H), 0.85 (d, J = 6.7 Hz, 1.5H), 0.81 (t, J = 7.3 Hz, 
1.5H), 0.76 (d, J = 6.7 Hz, 1.5H), 0.75 (t, J = 7.6 Hz, 1.5H). 
82 
 
13
C NMR (150 MHz, DMSO-d6) δ 172.7 (0.5C), 172.66 (0.5C), 171.9 (0.5C), 171.5 (0.5C), 171.1 (0.5C), 
170.8 (0.5C), 154.3 (0.5C), 153.9 (0.5C), 144.1 (0.5C), 143.83 (0.5C), 143.76 (0.5C), 143.5 (0.5C), 140.7, 
140.6 (0.5C), 140.5 (0.5C), 137.8 (0.5C), 137.7 (0.5C), 129.2, 129.1, 127.9, 127.6, 127.5, 127.14, 127.08, 
126.1, 125.9 (0.5C), 125.6 (0.5C), 125.15, 125.06, 120.1, 120.0, 66.9 (0.5C), 66.6 (0.5C), 59.9 (0.5C), 59.6 
(0.5C), 56.4 (0.5C), 56.3 (0.5C), 53.6 (0.5C), 53.5 (0.5C), 47.1 (0.5C), 46.6 (0.5C), 46.5 (0.5C), 46.4 (0.5C), 
37.3 (0.5C), 36.8 (0.5C), 36.5 (0.5C), 36.4 (0.5C), 31.1 (0.5C), 29.6 (0.5C), 24.65 (0.5C), 24.58 (0.5C), 23.6 
(0.5C), 22.7 (0.5C), 15.4 (0.5C), 15.3 (0.5C), 11.2. 
IR (CHCl3) 3409, 3353, 3066, 3027, 3007, 2968, 2935, 2879, 1683, 1513, 1451, 1416, 1356, 1336, 1240, 
1192, 1122, 1053, 1030, 1013, 986, 949, 922, 890, 865, 823, 701 cm
–1
. 
HRMS (ESI) m/z 642.2550 (calcd for C35H38N3Na2O6 [M–H+2Na]
+, ∆ –0.6 mmu). 
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3.5.5 Synthesis of Fmoc-L-Pro-L-Ile-OMe (12) 
 
 
 
To a stirred solution of H-Ile-OMe.HCl (5) (0.65 g, 4.0 mmol) in dry THF (5 mL) was added 7 
(Fmoc-Pro-OH, 0.86 g, 3 mmol) and the mixture was cooled to 0 
o
C. To the cooled mixture was added 
DIPEA (4.0 mL, 31 mmol) followed by DEPBT (7.0 g, 23.4 mmol). The resulting mixture was allowed to 
stir at room temperature for 12 h. The mixture was diluted with EtOAc (10 mL) and washed with 1 M aq. 
HCl (6 mL x 3), sat. NaHCO3 aq (6 mL x 3), and brine (6 mL x 3). The organic layer was dried with 
MgSO4 and concentrated. The crude material was separated with SiO2 column (5 g) in CHCl3/MeOH   
(9/1 → 0/1) to afford dipeptide 12 (1.1 g, 2.4 mmol, 94%) as a white solid. 
 
Rf = 0.43 (hexane/EtOAc = 2:1). 
m.p.: 109.5–110.5 ºC. 
[α]D
22
 –58 (c 1.0, CHCl3). 
1
H NMR (600 MHz, DMSO-d6) δ 8.41 (d, J = 8.1 Hz, 0.5H), 8.19 (d, J = 8.0 Hz, 0.5H), 7.89 (d, J = 10.3 Hz, 
1H), 7.88 (d, J = 8.0 Hz, 1H), 7.66 (dd, J = 10.3, 7.3 Hz, 1H), 7.62 (d, J = 7.4 Hz, 1H), 7.42 (t, J = 7.4 Hz, 
1H), 7.41 (d, J = 7.4 Hz, 1H), 7.37–7.27 (m, 2H), 4.54 (dd, J = 8.5, 2.9 Hz, 0.5H), 4.31 (dd, J = 8.7, 2.7 Hz, 
0.5H), 4.29–4.17 (m, 3H), 4.08 (t, J = 7.7 Hz, 0.5H), 4.01 (t, J = 8.5 Hz, 0.5H), 3.62 (s, 1.5H), 3.60 (s, 1.5H), 
3.50–3.28 (m, 2H), 2.26 (m, 0.5H), 2.08 (m, 0.5H), 1.95–1.72 (m, 4H), 1.43–1.32 (m, 1H), 1.23–1.08 (m, 
1H), 0.83 (d, J = 7.1 Hz, 1.5H), 0.82 (t, J = 7.6 Hz, 1.5H), 0.77 (d, J = 6.8 Hz, 1.5H), 0.68 (t, J = 7.4 Hz, 
1.5H). 
13
C NMR (150 MHz, DMSO-d6) δ 172.5 (0.5C), 172.1 (0.5C), 172.04 (0.5C), 171.98 (0.5C), 153.84 (0.5C), 
153.80 (0.5C), 143.90 (0.5C), 143.88 (0.5C), 143.76 (0.5C), 143.4 (0.5C), 140.7, 140.6 (0.5C), 140.5 (0.5C), 
127.7, 127.6, 127.2, 127.1, 125.6 (0.5C), 125.2 (0.5C), 125.12 (0.5C), 125.11 (0.5C), 120.12, 120.07, 67.0 
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(0.5C), 66.4 (0.5C), 59.1 (0.5C), 58.9 (0.5C), 56.4 (0.5C), 56.3 (0.5C), 51.6, 47.2 (0.5C), 46.6, 46.4 (0.5C), 
36.3 (0.5C), 36.2 (0.5C), 31.4 (0.5C), 29.9 (0.5C), 24.79 (0.5C), 24.76 (0.5C), 23.8 (0.5C), 22.9 (0.5C), 
15.42 (0.5C), 15.37 (0.5C), 11.2 (0.5C), 11.0 (0.5C). 
IR (CHCl3) 3420, 3339, 3012, 2967, 2879, 1738, 1685, 1516, 1451, 1418, 1355, 1336, 1121,1090, 1007, 986, 
774, 739 cm
–1
. 
HRMS (ESI) m/z 487.2209 (calcd for C27H32N2NaO5 [M+Na]
+, ∆ 0.0 mmu). 
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3.5.6 Synthesis of Fmoc-L-Phe-L-Pro-L-Ile-OMe (13) 
  
 
 
To a protected dipeptide 12 (9.0 g, 19 mmol) was added 20% piperidine in anhydrous DMF (15 mL). The 
solution was stirred for 1 h at room temperature and concentrated. The crude material was partially separated 
with silica-gel (6 g) in CHCl3/MeOH (9/1 → 0/1) to obtain a crude free amine (4.7 g). To a stirred solution 
of the crude free amine (4.7 g) in anhdrous THF (12 mL) was added 6 (Fmoc-L-Phe-OH, 8.0 g, 21 mmol) 
and the resulting mixture was cooled to 0 
o
C while stirring. To the cooled mixture was added DIPEA (5 mL, 
39 mmol) dropwise followed by the addition of DEPBT (12 g, 40 mmol). The resulting mixture was allowed 
to stir at 0 
o
C to ambient temperature for 16 h. The mixture was diluted with EtOAc (25 mL) and washed 
three times with 1 M aq. HCl (6 mL x 3), sat. NaHCO3 aq. (6 mL x 3), brine (6 mL x 3), dried with MgSO4 
overnight, and concentrated. The crude material was separated with SiO2 column (4 g) in CHCl3/MeOH  
(9/1 → 0/1) to afford tripeptide 13 (6.3 g, 10 mmol, 53%) as a white solid. 
 
Rf = 0.45 (CHCl3/MeOH = 9:1). 
m.p.: 42.5–46.5 ºC. 
[α]D
22
 −40 (c 0.87, CHCl3). 
1
H NMR (600 MHz, DMSO-d6) δ 8.16 (d, J = 8.0 Hz, 1H), 7.87 (d, J = 6.9 Hz, 2H), 7.78 (d, J = 8.5 Hz, 1H), 
7.65 (dd, J = 14.0, 7.5 Hz, 2H), 7.40 (dd, J = 13.0, 6.8 Hz, 2H), 7.36–7.17 (m, 7H), 4.49 (dd, J = 8.4, 3.8 Hz, 
1H), 4.40 (m, 1H), 4.22 (dd, J = 7.9, 6.2 Hz, 1H), 4.20–4.10 (m, 3H), 3.63 (s, 3H), 3.38–3.30 (m, 2H), 2.94 
(dd, J = 9.8, 3.5 Hz, 1H), 2.77 (dd, J = 9.7, 3.7 Hz, 1H), 2.07–2.00 (m, 1H), 1.97–1.73 (m, 4H), 1.41 (m, 1H), 
1.19 (m, 1H), 0.87 (d, J = 6.9 Hz, 3H), 0.86 (t, J = 7.6 Hz, 3H). 
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13
C NMR (150 MHz, DMSO-d6) δ 172.0, 171.6, 170.0, 155.9, 143.7, 140.6, 138.0, 129.3 (2C), 128.1 (2C), 
127.6 (2C), 127.0 (2C), 126.3, 125.3, 125.2, 120.0 (2C), 65.6, 59.0, 56.3, 54.3, 51.6, 46.7, 46.5, 36.4, 36.3, 
28.8, 24.7, 24.5, 15.4, 11.2. 
IR (CHCl3) 3427, 3027, 3011, 2966, 1733, 1716, 1675, 1645, 1232, 1201, 1183, 1149, 1082, 701 cm
–1
. 
HRMS (ESI) m/z 634.2892 (calcd for C36H41N3NaO6 [M+Na]
+,Δ −0.1 mmu). 
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3.5.7 Synthesis of Fmoc-L-Tyr(tBu)-L-Phe-L-Pro-L-Ile-OMe (4) 
 
 
 
To a tripeptide 13 (6.3 g, 10 mmol) was added 20% piperidine in anhydrous DMF (15 mL) dropwise. The 
solution was stirred for 1 h at room temperature and concentrated to afford a crude material. The crude 
material was partially separated with silica-gel (4.2 g) to obtain a crude amine (3.0 g). To a stirred solution of 
crude amine in anhydrous THF (8.0 mL) was added 8 (Fmoc-L-Tyr(tBu), 4.2 g, 9.3 mmol) and the resulting 
mixture was cooled to 0 
o
C while stirring. To the cooled mixture was added DIPEA (4 mL, 31 mmol) 
dropwise followed by the addition of DEPBT (4.2 g, 14 mmol). The resulting mixture was stirred at ambient 
temperature for 16 h. The mixture was diluted with EtOAc (25 mL) and washed with 1 M aq. HCl (7 mL x 
3), saturated aq. NaHCO3 (5 mL x 3), brine (5 mL x 3), dried with MgSO4, and concentrated. The crude 
material was separated with SiO2, column (6.1 g) in hexane/EtOAc (4/1 → 0/1) to afford tetrapeptide 4 (6.7 
g, 8.1 mmol, 73%) as a white solid. 
      
Rf = 0.42 (CHCl3/MeOH = 9:1).  
m.p.: 85.5–87.0 ºC.  
[α]D
22
 −33 (c 1.0, CHCl3).  
1
H NMR (600 MHz, DMSO-d6) δ 8.22 (d, J = 8.0 Hz, 1H), 8.18 (d, J = 8.1 Hz, 1H), 7.87 (d, J = 7.6 Hz, 2H), 
7.63 (t, J = 7.0 Hz, 2H), 7.50 (d, J = 9.1 Hz, 1H), 7.43–7.37 (m, 2H), 7.35–7.10 (m, 9H), 6.77 (d, J = 8.4 Hz, 
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2H), 4.69 (td, J = 8.3, 4.8 Hz, 1H), 4.49 (dd, J = 8.5, 3.8 Hz, 1H), 4.27–4.04 (m, 5H), 3.63 (s, 3H), 3.53–3.47 
(m, 1H), 3.37–3.32 (m, 1H), 3.02 (dd, J = 14.0, 4.6 Hz, 1H), 2.86 (dd, J = 14.2, 3.9 Hz, 1H), 2.79 (dd, J = 
14.1, 8.7 Hz, 1H), 2.62 (dd, J = 13.7, 10.9 Hz, 1H), 2.07–1.98 (m, 1H), 1.95–1.76 (m, 4H), 1.47–1.37 (m, 
1H), 1.28–1.18 (m, 1H), 1.16 (s, 9H), 0.86 (d, J = 6.8 Hz, 3H), 0.85 (t, J = 7.3 Hz, 3H).  
13
C NMR (150 MHz, DMSO-d6) δ 172.0, 171.6, 171.1, 169.4, 159.2, 155.6, 143.7 (2C), 140.6 (2C), 137.4 
(2C), 129.7 (2C), 129.4 (2C), 128.1 (2C), 127.6 (2C), 127.0 (2C), 126.3, 125.3 (2C), 123.2 (2C), 120.4, 
120.1 (2C), 77.5, 65.7, 59.0, 56.3, 56.1, 52.0, 51.6, 46.8, 46.5, 37.0, 36.8, 36.4, 28.9, 28.5 (3C), 24.7, 24.5, 
15.5, 11.3.  
IR (CHCl3) 3420, 3027, 3010, 2979, 1733, 1673, 1637, 1506, 1449, 1236, 1160 cm
–1
.  
HRMS (ESI) m/z 853.4137 (calcd for C49H58N4NaO8 [M+Na]
+, Δ −1.5 mmu). 
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3.5.8 Synthesis of Fmoc-L-Pro-L-Phe-L-Ile-L-Tyr(tBu)-L-Phe-L-Pro-L-Ile-OMe (2) 
 
 
 
The tetrapeptide 4 (2.0 g, 2.4 mmol) was dissolved with 20% piperidine in anhydrous DMF (10 mL) 
and allowed to stir for 1 hour at room temperature and then concentrated. The crude material was partially 
separated in SiO2 column (2 g) with CHCl3/MeOH (9/1 → 0/1) to afford crude amine (1.3 g) and used in the 
next reaction without further purification. To a solution of crude amine (0.41 g) and carboxylic acid 14 (0.54 
g, 0.9 mmol) in anhydrous THF (10 mL) was added DIPEA (0.5 mL, 4 mmol) and DEPBT (1.0 g, 3.3 mmol). 
The reaction mixture was stirred at room temperature for 24 h. The crude reaction mixture was diluted with 
EtOAc (25 mL) and washed with aq. 1 M HCl (5 mL x 3), saturated NaHCO3 aq. (5 mL x 3), and brine (5 
mL x 3). The organic layer was dried in MgSO4 and concentrated. The crude material was separated with 
ODS silica gel (2.2 g) to afford a protected linear peptide 2 (535 mg, 66% from 14) as a white solid. 
 
Rf = 0.60 (CHCl3/MeOH = 9:1). 
m.p.: 118.5–120.0 ºC. 
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[α]D
22
 −70 (c 1.0, CHCl3). 
1
H NMR (600 MHz, DMSO-d6) δ 8.25–8.10 (m, 2H), 8.00 (d, J = 7.9 Hz, 0.5H), 7.95–7.85 (m, 3H), 
7.73–7.61 (m, 1H), 7.55 (d, J = 7.6 Hz, 0.5H), 7.52 (d, J = 7.6 Hz, 0.5H), 7.46–7.02 (m, 16H), 6.92–6.75 (m, 
3.5H), 4.70–4.60 (m, 1.5H), 4.58–4.42 (m, 2.5H), 4.38–4.05 (m, 5H), 3.90–3.80 (m, 1H), 3.63 (s, 3H), 
3.55–3.35 (m, 2H), 3.03–2.62 (m, 6.5H), 2.14 (m, 0.5H), 2.08–1.50 (m, 10H), 1.50–1.34 (m, 1H), 1.34–1.12 
(m, 13H), 0.90–0.78 (m, 6H), 0.76–0.56 (m, 6H). 
13
C NMR (150 MHz, DMSO-d6) δ 172.0, 171.7 (0.5C), 171.6, 170.9 (0.5C), 170.7 (0.5C), 170.6, 170.3 
(0.5C), 170.0 (0.5C), 169.1, 168.9 (0.5C), 154.2 (0.5C), 153.9 (0.5C), 153.4 (0.5C), 153.3 (0.5C), 144.1 
(0.5C), 143.8 (0.5C), 143.7 (0.5C), 143.4 (0.5C), 140.74 (0.5C), 140.72 (0.5C), 140.6 (0.5C), 140.5 (0.5C), 
137.9 (0.5C), 137.8 (0.5C), 137.42 (0.5C), 137.38 (0.5C), 129.5, 129.3 (2C), 129.1, 129.0, 128.7 (0.5C), 
128.2 (0.5C), 128.0 (2C), 127.9, 127.7, 127.5, 127.1, 127.0, 126.9 (0.5C), 126.3 (0.5C), 126.2, 126.1 (0.5C), 
125.7 (0.5C), 125.6 (0.5C), 125.5 (0.5C), 125.3 (0.5C), 125.1, 125.0 (0.5C), 123.2 (2C), 120.1, 120.0, 77.45 
(0.5C), 77.40 (0.5C), 66.9 (0.5C), 66.6 (0.5C), 59.9 (0.5C), 59.5 (0.5C), 58.9, 56.9 (0.5C), 56.8 (0.5C), 56.6 
(0.5C), 56.3 (0.5C), 53.7 (0.5C), 53.6 (0.5C), 53.4 (0.5C), 53.3 (0.5C), 51.9, 51.6 (0.5C), 51.5 (0.5C), 47.1 
(0.5C), 46.7, 46.6 (0.5C), 46.4, 38.2, 37.2 (0.5C), 37.1 (0.5C), 36.9 (0.5C), 36.8 (0.5C), 36.6, 36.5 (0.5C), 
36.4 (0.5C), 31.1 (0.5C), 29.6 (0.5C), 28.8, 28.5 (3C), 24.7, 24.4, 24.1, 23.6 (0.5C), 22.6 (0.5C), 15.4, 15.1 
(0.5C), 15.0 (0.5C), 11.2 (0.5C), 11.1 (0.5C), 10.83 (0.5C), 10.79 (0.5C). 
IR (CHCl3) 3405, 3332, 3028, 3010, 2971, 2935, 2879, 1738, 1674, 1508, 1452, 1439, 1421, 1355, 1338, 
1237, 1161, 1128, 1092, 986, 922, 895, 850, 702 cm
–1
. 
HRMS (ESI) m/z 1210.6201 (calcd for C69H85N7NaO11 [M+Na]
+, Δ −0.4 mmu). 
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3.5.9 Synthesis of H-L-Pro-L-Phe-L-Ile-L-Tyr(tBu)-L-Phe-L-Pro-L-Ile-OH (16) 
 
 
To a stirred solution of protected linear peptide 2 (0.35 g, 0.29 mmol) in anhydrous 1,2-DCE (4 mL) 
was added Me3SnOH (0.32 g, 1.7 mmol) and stirred for 8 h at 78 
o
C. The reaction mixture was concentrated 
in vacuo, dissolved in EtOAc, washed with aq. 5% HCl (5 mL x 3), and brine (5 mL x 3). The organic layer 
was dried in MgSO4 and concentrated. The crude material was separated with ODS open column (700 mg) in 
MeOH (40 → 100%) to afford a free amine intermediate (170 mg, 54%). The free amine dissolved in 20% 
piperidine in anhydrous DMF (10 mL) and allowed to stir at room temperature for 1 h and then concentrated. 
The crude material was separated in ODS open column (500 mg) with MeOH (60 → 100%) to afford 16 
(112 mg, 80%) as a white solid.  
 
Rf = 0.45 (CHCl3/MeOH = 2:1).  
m.p.: 190.0–192.0 ºC. 
[α]D
22
 +20 (c 0.74, MeOH). 
1
H NMR (600 MHz, DMSO-d6) δ 8.39 (d, J = 7.6 Hz, 1H), 8.28 (d, J = 7.9 Hz, 1H), 8.13 (d, J = 8.7 Hz, 1H), 
8.04 (d, J = 7.6 Hz, 1H), 7.87 (d, J = 8.1 Hz, 1H), 7.32–7.05 (m, 12H), 6.79 (d, J = 8.4 Hz, 2H), 4.68–4.63 
(m, 1H), 4.60 (td, J = 9.3, 4.2 Hz, 1H), 4.55–4.42 (m, 2H), 4.18–4.06 (m, 3H), 3.75–3.20 (m, 4H), 3.05–2.70 
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(m, 6H), 2.02–1.90 (m, 2H), 1.90–1.74 (m, 4H), 1.70–1.38 (m, 6H), 1.33 (m, 1H), 1.21 (s, 9H), 0.98 (m, 1H), 
0.86 (d, J = 6.7 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H), 0.75 (t, J = 7.1 Hz, 3H), 0.66 (d, J = 6.7 Hz, 3H). 
13
C NMR (150 MHz, DMSO-d6) δ 173.1, 171.1, 170.7 170.53, 170.52, 170.4, 169.3, 153.4, 137.51, 137.48, 
129.6 (2C), 129.3 (2C), 129.2 (2C), 128.3 (2C), 128.1 (2C), 127.9 (2C), 126.3, 126.2, 123.2, 77.5, 59.5, 59.2, 
57.0, 56.5, 53.6, 53.3, 51.9, 46.7, 46.1, 37.65, 37.63, 37.0, 36.9, 36.7, 30.0, 28.8, 28.5 (3C), 24.7, 24.6, 24.4, 
24.2, 15.6, 15.2, 11.5, 10.9 cm
–1
. 
IR (KBr) 3293, 3063, 2968, 2932, 2876, 1644, 1537, 1508, 1454, 1237, 1161, 1117, 1034, 951, 925, 899, 
849, 746, 701 cm
–1
. 
HRMS (ESI) m/z 974.5377 (calcd for C53H73N7NaO9 [M+Na]
+, Δ +1.0 mmu). 
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3.6.0 Synthesis of cyclo[L-Pro-L-Phe-L-Ile-L-Tyr(tBu)-L-Phe-L-Pro-L-Ile] (9a) and 
D-allo-Ile
5
 epimer (9b) 
 
 
 
To a stirring solution of 16 (6.0 mg, 6.3 μmol) in anhydrous DMF (2 mL) was added DIEPA (5 μL, 39 μL) 
and DEPBT (3 mg, 10 μmol). Sodium chloride (NaCl) (0.9 mg, 15.4 μm) was dissolved in distilled water (25 
μL) separately and added to the mixture. The reaction mixture was allowed to stir at room temperature for 24 
h. The mixture was concentrated and separated with reverse phase HPLC (Devolosil ODS-HG-5, ɸ 20 × 250 
mm) in 85% MeOH to afford 9a (3.9 mg. 61%) and 9b (1.2 mg, 20%) as white solids.   
 
Compound 9a  
Rf = 0.63 (CHCl3/MeOH = 9:1). 
m.p.: 150.0–154.0 ºC. 
[α]D
22
 −87 (c 0.74, CHCl3). 
1
H NMR (600 MHz, CD3OD) δ 7.35–7.26 (m, 7H), 7.23–7.15 (m, 5H), 6.98 (d, J = 8.5 Hz, 2H), 4.42 (m, 
1H), 4.38 (d, J = 11.1 Hz, 1H), 4.30 (d, J = 11.2 Hz, 1H), 4.23 (dd, J = 9.5, 2.9 Hz, 1H), 4.05 (dd, J = 11.8, 
4.5 Hz, 1H), 3.89 (t, J = 8.7 Hz, 1H), 3.87 (dd, J = 12.1, 4.3 Hz, 1H), 3.61 (m, 1H), 3.54 (t, J = 13.5 Hz, 1H), 
3.41 (dd, J = 10.1, 4.6 Hz, 2H), 3.35 (dd, J = 12.9, 4.3 Hz, 2H), 3.31 (m, 1H), 3.27 (dd, J = 13.1, 2.9 Hz, 1H), 
2.98 (dd, J = 13.1, 9.5 Hz, 1H), 2.92 (dd, J = 12.4, 4.5 Hz, 1H), 2.78 (t, J = 12.1 Hz, 1H), 2.14 (m, 1H), 2.07 
(m, 1H), 2.02 (dd, J = 12.2, 6.0 Hz, 1H), 1.92–1.70 (m, 4H), 1.67–1.52 (m, 3H), 1.44 (m, 1H), 1.34 (s, 9H), 
1.29 (m, 1H), 1.20 (m, 1H), 0.96 (d, J = 7.0 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H), 0.90 (t, J = 7.2 Hz, 3H), 0.88 
(t, J = 7.5 Hz, 3H). 
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13
C NMR (150 MHz, CD3OD) δ 174.7, 173.0, 172.9, 172.7, 172.3, 172.2, 171.6, 155.5, 140.1, 136.7, 133.1, 
132.1 (2C), 130.7 (2C), 130.4 (2C), 130.2 (2C), 129.6 (2C), 128.9, 127.8, 125.2 (2C), 79.6, 62.9, 62.6, 61.6, 
59.9, 57.6, 57.3, 56.3, 49.7, 47.7, 38.6, 38.5, 38.3, 36.7, 35.7, 31.6, 31.0, 29.3 (3C), 26.3, 26.1, 25.9, 23.0, 
16.2, 15.4, 10.6, 10.2. 
IR (CHCl3) 3419, 3356, 3264, 3007, 2980, 2968, 2933, 2878, 1647, 1508, 1446, 1237, 1286, 1160, 897, 768, 
756, 746, 732, 702 cm
–1
. 
HRMS (ESI) m/z 956.5269 (calcd for C53H71N7NaO8 [M+Na]
+
, Δ +0.7 mmu). 
 
Compound 9b  
Rf = 0.60 (CHCl3/MeOH = 9:1). 
m.p.: 152.0–155.5 ºC. 
[α]D
22
 −39 (c 0.38, CHCl3). 
1
H NMR (600 MHz, CD3OD) δ 7.37–7.27 (m, 7H), 7.27–7.20 (m, 3H), 7.11 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 
8.5 Hz, 2H), 4.36 (dd, J = 8.8, 1.9 Hz, 1H), 4.29 (dd, J = 10.0, 4.3 Hz, 1H), 4.24 (t, J = 8.2 Hz, 1H), 3.70 (t, J 
= 8.3 Hz, 1H), 3.62 (d, J = 9.8 Hz, 1H), 3.60 (m, 1H), 3.51 (td, J = 9.7, 6.7 Hz, 1H), 3.40 (dd, J = 13.9, 3.8 
Hz, 1H), 3.10 (dd, J = 14.4, 4.3 Hz, 1H), 3.06 (t, J = 13.4 Hz, 1H), 3.04 (t, J = 7.3 Hz, 1H), 2.98 (m, 1H), 
2.88 (dd, J = 14.3, 10.3 Hz, 1H), 2.75 (dd, J = 13.7, 7.4 Hz, 1H), 2.20 (m, 1H), 2.08–1.80 (m, 7H), 1.79–1.69 
(m, 2H), 1.51 (m, 1H), 1.37 (m, 1H), 1.27 (s, 9H), 1.27–1.21 (m, 2H), 1.11 (m, 1H), 1.00 (t, J = 7.3 Hz, 3H), 
0.94 (m, 1H), 0.91 (d, J = 6.8 Hz, 3H), 0.85 (m, 1H), 0.84 (t, J = 7.3 Hz, 3H), 0.59 (d, J = 6.8 Hz, 3H). 
13
C NMR (150 MHz, CD3OD) δ 175.0, 174.9, 174.4, 174.2, 173.8, 173.3, 171.4, 155.8, 139.0, 137.8, 133.2, 
130.93 (2C), 130.89 (2C), 130.5 (2C), 129.82 (2C), 129.76 (2C), 128.2, 128.1, 125.5 (2C), 79.7, 64.2, 63.1, 
62.5, 58.1, 55.9, 55.2, 53.9, 49.7, 48.6, 40.2, 39.1, 37.8, 37.2, 35.5, 31.0, 30.1, 29.3 (3C), 27.9, 26.7, 26.5, 
25.2, 15.9, 14.8, 12.3, 10.8. 
IR (CHCl3) 3402, 3311, 3007, 2970, 2933, 2879, 1676, 1637, 1531, 1507, 1455, 1238, 1160, 996, 896, 859, 
830, 701 cm
–1
. 
HRMS (ESI) m/z 956.5264 (calcd for C53H71N7NaO8 [M+Na]
+
, Δ +0.2 mmu). 
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3.6.1 Synthesis of cyclo[L-Tyr-L-Ile-L-Phe-L-Pro-L-Ile-L-Pro-L-Phe] (1) 
 
 
The protected cyclic peptide 9a (1.5 mg, 2 μmol) was dissolved in 95% TFA (1.2 mL) and stirred for 1 
h at room temperature and concentrated. The crude material was separated with reverse phase HPLC 
(Develosil ODS-HG-5, ɸ 20 × 250 mm) in 85% MeOH to afford 1 (1.2 mg, 85%) as an off-white solid. 
   
Rf = 0.85 (CHCl3 / MeOH = 4:1). 
[α]D
23
 −84 (c 0.11, MeOH).  
1
H NMR (600 MHz, CD3OD) δ 7.33–7.27 (m, 6H), 7.24 (d, J = 8.4 Hz, 2H), 7.18 (d, J = 7.8 Hz, 2H), 7.17 (d, 
J = 7.2 Hz, 2H), 6.77 (d, J = 8.4 Hz, 2H), 4.41 (m, 1H), 4.39 (d, J = 10.8 Hz, 1H), 4.30 (d, J = 11.4 Hz, 1H), 
4.19 (dd, J = 9.5, 2.9 Hz, 1H), 4.05 (dd, J = 11.7, 4.5 Hz, 1H), 3.89 (t, J = 8.4 Hz, 1H), 3.87 (dd, J = 12.0, 4.2 
Hz, 1H), 3.61 (m, 1H), 3.55 (dd, J = 13.2, 12.6 Hz, 1H), 3.42 (dd, J = 9.6, 4.2 Hz, 2H), 3.34 (dd, J = 13.2, 4.2 
Hz, 1H), 3.31 (m, 1H), 3.19 (dd, J = 13.2, 2.4 Hz, 1H), 2.94–2.89 (m, 2H), 2.82 (t, J = 12.1 Hz, 1H), 2.14 (m, 
1H), 2.07 (m, 1H), 2.02 (dd, J = 12.0, 6.0 Hz, 1H), 1.89–1.72 (m, 5H), 1.65–1.55 (m, 3H), 1.44 (m, 1H), 1.29 
(m, 1H), 1.19 (m, 1H), 0.96 (d, J = 6.0 Hz, 6H), 0.91 (t, J = 7.2 Hz, 3H), 0.88 (t, J = 7.2 Hz, 3H). 
13
C NMR (150 MHz, CD3OD) δ 174.5, 172.9, 172.7, 172.5, 172.23, 172.21, 171.6, 157.4, 140.0, 136.6, 
132.4 (2C), 130.6 (2C), 130.3 (2C), 130.1 (2C), 129.5 (2C), 128.8, 128.7, 127.7, 116.1 (2C), 62.7, 62.5, 61.5, 
59.8, 57.7, 57.2, 56.3, 49.9, 49.6, 47.5, 38.4, 38.1, 36.5, 35.5, 31.5, 30.8, 26.1, 25.9, 25.7, 22.8, 16.1, 15.3, 
10.5, 10.1.  
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IR (CHCl3) 3344, 3259, 3007, 2966, 2932, 2878, 1643, 1516, 1447, 1349, 1282, 1241, 1188, 1173, 1080, 
1009, 989, 916, 894, 831, 703 cm
–1
.  
HRMS (ESI) m/z 900.4653, calcd for C49H63N7O8Na [M+Na]
 + 
, 900.4636 (△-0.002 mmu).  
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3.6.2 Synthesis of cyclo[L-Tyr-L-Ile-L-Phe-L-Pro-D-allo-Ile-L-Pro-L-Phe] (10) 
 
 
The protected cyclic peptide 9b (2.1 mg, 2.2 μmol) was dissolved with 95% TFA (2.0 mL) and stirred for 
1 h at room temperature and concentrated. The crude material was separated with reverse phase HPLC 
(ODS-HG-5, ɸ 20 × 250 mm) in 85→100% MeOH to afford 10 (1.9 mg, 87%) as an off-white solid.   
 
Rf = 0.49 (CHCl3/MeOH = 9:1). 
m.p.: 158.5–162.0 ºC. 
[α]D
22
 −31 (c 0.21, CHCl3). 
1
H NMR (600 MHz, CD3OD) δ 7.37–7.27 (m, 7H), 7.27–7.20 (m, 3H), 6.99 (d, J = 8.4 Hz, 2H), 6.68 (d, J = 
8.4 Hz, 2H), 4.35 (dd, J = 9.1, 2.2 Hz, 1H), 4.27 (dd, J = 9.4, 4.6 Hz, 1H), 4.23 (m, 1H), 3.70 (br t, J = 9.2 
Hz, 1H), 3.65 (d, J = 9.4 Hz, 1H), 3.58 (m, 1H), 3.50 (td, J = 9.8, 6.4 Hz, 1H), 3.05–2.99 (m, 3H), 2.95 (m, 
1H), 2.84 (dd, J = 14.5, 9.5 Hz, 1H), 2.78 (dd, J = 13.6, 7.2 Hz, 1H), 2.20 (m, 1H), 2.05 (m, 1H), 2.00–1.80 
(m, 7H), 1.75 (m, 1H), 1.71 (m, 1H), 1.48 (m, 1H), 1.38 (m, 1H), 1.29–1.20 (m, 2H), 1.12 (m, 1H), 1.00 (t, J 
= 7.3 Hz, 3H), 0.94 (m, 1H), 0.91 (d, J = 6.8 Hz, 3H), 0.85 (m, 1H), 0.86 (t, J = 7.3 Hz, 3H), 0.64 (d, J = 6.8 
Hz, 3H). 
13
C NMR (150 MHz, CD3OD) δ 175.0, 174.9, 174.4, 174.1, 173.8, 173.4, 171.3, 155.2, 144.0, 138.9, 137.8, 
131.5 (2C), 130.9 (2C), 130.6 (2C), 129.8 (2C), 129.8 (2C), 128.2, 128.1, 116.6 (2C), 64.1, 63.1, 62.5, 58.0, 
57.6, 55.2, 54.0, 51.0, 45.1, 40.2, 37.8, 37.2, 35.7, 31.0, 30.12, 30.05, 27.9, 26.6, 26.5, 25.2, 15.8, 14.8, 12.2, 
10.9.  
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IR (CHCl3) 3393, 3299, 3006, 2966, 2932, 2879, 2360, 2341, 1674, 1636, 1557, 1541, 1516, 1456, 1339, 
1264, 1200, 1173, 995, 919, 832, 720, 701 cm
–1
. 
HRMS (ESI) m/z 900.4639 (calcd for C49H63N7NaO8 [M+Na]
+
, Δ +0.3 mmu). 
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Chapter 4. Future Studies and Conclusion 
4.1 Future Studies 
 
Introduction of different functional groups into the peptide results in greater stability and lipophilicity of 
the molecules and often changes their physical, chemical, and physiological properties. N-methylation of 
peptides has proven to be one of the resourceful processes. It also alters the conformation and stereostructure 
of the peptides and provides a rigid structure. It increases permeability across the cell membrane, prevents 
intramolecular hydrogen bonding sites and protects it from enzymatic degradation. Therefore, these changes 
in the chemical structures of the peptides might increase the bioavailability and therapeutic potential of the 
peptides.
[1, 2]
 These properties are very important in developing peptides as medicines or pharmaceutical 
agent.
[3]
  
A fluorine atom or fluorinated groups are important structural modification in diverse class of bioactive 
organic molecules. The presence of C-F (carbon-fluorine) bond is isosteric compared to a C-H bond, but 
results in greater stability and lipophilicity of the molecules and often alter their physical, chemical, and 
physiological properties of the molecule due to the strong dipole moment of the C-F bond.
[4]
 These changes 
have been exploited in the pharmaceutical and agrochemical fields, where the replacement of a C-H with C-F 
fine tunes biological activity. Despite the scarcity of fluorinated natural products, fluorinated compounds are 
common in modern society, and approximately 20% of commercial pharmaceuticals and 30% of 
agrochemicals contain fluorine.
[5]
 Therefore, a small library of N-methylated analogs (2-4) and fluorinated 
analogs (5-7), of stylissatin A (1) will be prepared for the purpose of further biological and conformational 
studies. 
 
 
Figure 39. Analogs of stylissatin A (1) 
102 
 
4. 2 Conclusion 
 
The marine sponge Stylissa massa has proven to be a rich source of bioactive compounds where a novel 
cyclic heptapeptide, stylissatin A (1), and three known compounds were isolated via bioassay-guided 
separation as described in Chapter 2 (Figure 40). One- and two-dimensional (1D/2D) NMR techniques were 
applied to determine the partial structures of stylissatin A, while NOESY, HMBC and MS/MS fragmentation 
analysis were utilized to determine the amino acid sequence and connectivity. The absolute stereochemistry 
of 1 was determined by Marfey’s method, which revealed that all amino acid residues have L-configuration. 
Similarly, structures of three isolated compounds were elucidated.   
 
 
 
Figure 40. Compounds isolated from marine Stylissa massa 
    
To confirm the structure and bioactivity of stylissatin A, its synthesis was designed and conducted in 
solution phase as described in Chapter 3. In brief, coupling of Fmoc-protected amino acids and using 5 as a 
starting material to prepare 3 and 4 (Scheme 19).  
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Scheme 19. Synthesis of segments 1 (3) and 2 (4)  
 
Condensation of segments 1 and 2 resulted in 2. After the deprotection of 2, it was cyclized to afford 1 
(Scheme 20). The macrolactamization was conducted in the presence of DEPBT as a cyclization reagent, 
DIPEA as a base, and NaCl as an alkali metal ion additive to obtain the desired material as a major product 
(61%). In this condition, the Na
+
 promoted the peptide macrolactamization of linear peptide by binding the 
amidic oxygen which faciliated the N- and C-termini in close proximity to cyclize. Though the synthesis 
stylissatin A was successful, epimerization was encountered as a result of steric hindrance caused by 
isoleucine moieties at the site of segment condensation and macrolactamization. As a result, an epimerized 
product D-allo-Ile
5
 isomer 10 was obtained. In order to prevent epimerization, the carboxylic acid of proline 
moieties will be introduced at the site of condensation and cyclization in the future studies.  
 
 
Scheme 20. Synthesis of stylissatin A (1) 
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The spectroscopic data for synthetic stylissatin A agreed with the natural product which showed that 1 
was successfully synthesized. The optical rotation for synthetic 1 [α]D
25
 −84 (c 0.11, MeOH) was higher than 
the natural product [α]D
25
 −27 (c 0.11, MeOH). However, the signs or the direction for the light polarization 
was same for the synthetic and natural 1.    
The bioactivity of the synthetic products 1 and 10 and the tert-butyl ether analogs (9a and 9b) for 
inhibition of NO production was evaluated. The synthetic stylissatin A (1) showed weak inhibitory effects on 
NO production with negligible cytotoxicity (EC50 = 73 μM). Interestingly, the tert-butyl ether analogs 9a and 
9b showed potent inhibitory effects on NO production compared to 1 and 10. The bioassay results indicated 
that the hydroxy group of 1 could readily be modified to develop suitable chemical probes to investigate the 
mode of actions of stylissatin A (1) and its derivatives (Figure 41). 
 
 
 
Figure 41. Stylissatin A (1) and its synthetic derivatives 
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